ThermoGenesis (THMO) 10-K 24 Mar 20 2019 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Mar. 19, 2020	Jun. 28, 2019
Document Information [Line Items]
Entity Registrant Name	ThermoGenesis Holdings, Inc.
Entity Central Index Key	0000811212
Trading Symbol	thmo
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding (in shares)		4,561,017
Entity Public Float			$ 4,733
Entity Shell Company	false
Document Type	10-K
Document Period End Date	Dec. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	FY
Amendment Flag	false
Title of 12(b) Security	Common Stock, $.001 par value

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 3,157,000	$ 2,400,000
Restricted cash	1,000,000
Accounts receivable, net of allowance for doubtful accounts of $226,000 ($419,000 at December 31, 2018)	1,278,000	1,509,000
Inventories, net of reserves of $350,000 ($258,000 at December 31, 2018)	3,824,000	4,493,000
Prepaid expenses and other current assets	602,000	224,000
Total current assets	9,861,000	8,626,000
Restricted cash – long term		1,000,000
Equipment and leasehold improvements, net	2,028,000	2,562,000
Right-of-use operating lease assets, net	859,000
Goodwill	781,000	781,000
Intangible assets, net	1,467,000	1,591,000
Other assets	218,000	51,000
Total assets	15,214,000	14,611,000
Current liabilities:
Accounts payable	1,447,000	2,423,000
Accrued payroll and related expenses	288,000	703,000
Deferred revenue – short term	620,000	485,000
Interest payable – related party	1,869,000	1,513,000
Other current liabilities	2,461,000	1,241,000
Total current liabilities	6,685,000	6,365,000
Convertible promissory note – related party, less debt discount of $5,195,000 ($6,026,000 at December 31, 2018)	3,518,000	1,174,000
Convertible promissory note, plus debt premium of $46,000 ($0 at December 31, 2018)	413,000
Note payable	1,000,000
Operating lease obligations – long term	761,000
Deferred revenue – long term	1,901,000	303,000
Other noncurrent liabilities	20,000	38,000
Total liabilities	14,298,000	7,880,000
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value; 2,000,000 shares authorized; none issued and outstanding
Common stock, $0.001 par value; 350,000,000 shares authorized; 2,843,601 issued and outstanding (2,168,337 at December 31, 2018)	3,000	2,000
Additional paid in capital	237,313,000	235,888,000
Accumulated deficit	(236,932,000)	(227,435,000)
Accumulated other comprehensive loss	2,000	(13,000)
Total ThermoGenesis Holdings, Inc. stockholders’ equity	386,000	8,442,000
Noncontrolling interest	530,000	(1,711,000)
Total equity	916,000	6,731,000
Total liabilities and equity	$ 15,214,000	$ 14,611,000

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Accounts receivable, allowance for doubtful accounts	$ 226,000	$ 419,000
Inventories, reserves	350,000	258,000
Debt discount	$ 46,000	$ 0
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	2,000,000	2,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	350,000,000	350,000,000
Common stock, shares issued (in shares)	2,843,601	2,168,337
Common stock, shares outstanding (in shares)	2,843,601	2,168,337
Convertible Promissory Note [Member]
Debt discount	$ 5,195,000	$ 6,026,000

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Net revenues	$ 12,160,000	$ 9,003,000
Net revenues – related party	887,000	669,000
Total net revenues	13,047,000	9,672,000
Cost of revenues	7,351,000	7,479,000
Gross profit	5,696,000	2,193,000
Expenses:
Sales and marketing	1,656,000	1,359,000
Research and development	2,396,000	3,012,000
General and administrative	6,377,000	8,286,000
Impairment charges		33,081,000
Total operating expenses	10,429,000	45,738,000
Loss from operations	(4,733,000)	(43,545,000)
Fair value change of derivative instruments	1,000	596,000
Interest expense	(4,479,000)	(2,697,000)
Loss on extinguishment of debt	(840,000)
Loss on equity method investments	(15,000)
Other expenses	(33,000)	(24,000)
Total other expense	(5,366,000)	(2,125,000)
Loss before benefit for income taxes	(10,099,000)	(45,670,000)
Benefit for income taxes	0	4,730,000
Net loss	(10,099,000)	(40,940,000)
Loss attributable to non-controlling interests	(602,000)	(1,224,000)
Net loss attributable to common stockholders	(9,497,000)	(39,716,000)
Net loss	(10,099,000)	(40,940,000)
Other comprehensive loss:
Foreign currency translation adjustments	15,000	30,000
Comprehensive loss	(10,084,000)	(40,910,000)
Comprehensive loss attributable to non-controlling interests	(602,000)	(1,224,000)
Comprehensive loss attributable to common stockholders	$ (9,482,000)	$ (39,686,000)
Per share data:
Basic and diluted net loss per common share (in dollars per share)	$ (3.36)	$ (21.57)
Weighted average common shares outstanding Basic and diluted (in shares)	2,828,606	1,841,281

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]		Noncontrolling Interest [Member]	Total
Balance (in shares) at Dec. 31, 2017	1,090,664
Balance at Dec. 31, 2017	$ 1,000	$ 221,381,000	$ (187,640,000)	$ (43,000)	[1]	$ (487,000)	$ 33,212,000
Stock-based compensation expense (in shares)	41
Stock-based compensation expense		652,000					652,000
Issuance of common stock and pre-funded warrants in financing, net of offering costs (in shares)	808,465
Issuance of common stock and pre-funded warrants in financing, net of offering costs	$ 1,000	6,628,000					6,629,000
Exercise of warrants (in shares)	269,167
Exercise of warrants		27,000					27,000
Discount due to beneficial conversion features		7,200,000			[1]		7,200,000
Cumulative-effect adjustment from adoption of ASC 606			(79,000)				(79,000)
Foreign currency translation				30,000	[1]		30,000
Net loss			(39,716,000)		[1]	(1,224,000)	(40,940,000)
Balance (in shares) at Dec. 31, 2018	2,168,337
Balance at Dec. 31, 2018	$ 2,000	235,888,000	(227,435,000)	(13,000)	[1]	(1,711,000)	6,731,000
Stock-based compensation expense		614,000			[1]		614,000
Issuance of common stock and pre-funded warrants in financing, net of offering costs (in shares)
Issuance of common stock and pre-funded warrants in financing, net of offering costs		756,000					756,000
Exercise of warrants (in shares)	18,764
Exercise of warrants		112,000					112,000
Discount due to beneficial conversion features		2,313,000			[1]		2,313,000
Foreign currency translation				15,000	[1]		15,000
Net loss			(9,497,000)		[1]	(602,000)	(10,099,000)
Exercise of pre-funded warrants (in shares)	416,500
Exercise of pre-funded warrants	$ 1,000	41,000			[1]		42,000
Conversion of note payable to stock (in shares)	240,000
Conversion of note payable to stock		432,000			[1]		432,000
Reorganization of subsidiary and related change in non-controlling interest		(2,843,000)			[1]	2,843,000
Balance (in shares) at Dec. 31, 2019	2,843,601
Balance at Dec. 31, 2019	$ 3,000	$ 237,313,000	$ (236,932,000)	$ 2,000	[1]	$ 530,000	$ 916,000
[1]	Accumulated other comprehensive loss.

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Cash flows from operating activities:
Net loss	$ (10,099,000)	$ (40,940,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	805,000	670,000
Stock-based compensation expense	614,000	652,000
Amortization of debt discount/premium, net	2,349,000	1,174,000
(Recovery of) reserve for excess and slow-moving inventories	92,000	(11,000)
(Recovery of) reserve for bad debt expense	(60,000)	153,000
Change in fair value of derivative obligation	(1,000)	(596,000)
Deferred income tax benefit		(4,730,000)
Loss on disposal of equipment	70,000	1,360,000
Loss on extinguishment of debt	840,000
Impairment of intangible asset		33,081,000
Net change in operating assets and liabilities:
Accounts receivable	301,000	1,045,000
Inventories	610,000	61,000
Prepaid expenses and other assets	(525,000)	370,000
Accounts payable	(966,000)	214,000
Interest payable - related party	355,000	(606,000)
Accrued payroll and related expenses	(415,000)	172,000
Deferred revenue	135,000	24,000
Other current liabilities	1,143,000	922,000
Long term deferred revenue and other noncurrent liabilities	1,492,000	2,000
Net cash used in operating activities	(3,260,000)	(6,983,000)
Cash flows from investing activities:
Capital expenditures	(182,000)	(1,238,000)
Net cash used in investing activities	(182,000)	(1,238,000)
Cash flows from financing activities:
Proceeds from long-term debt	1,800,000
Proceeds from convertible promissory note-related party	1,513,000	500,000
Payments on finance lease obligations	(24,000)	(45,000)
Proceeds from issuance of common stock and pre-funded warrants	756,000	6,629,000
Proceeds from exercise of warrants and pre-funded warrants	154,000	27,000
Net cash provided by financing activities	4,199,000	7,111,000
Effects of foreign currency rate changes on cash and cash equivalents		(3,000)
Net decrease in cash, cash equivalents and restricted cash	757,000	(1,113,000)
Cash, cash equivalents and restricted cash at beginning of period	3,400,000	4,513,000
Cash, cash equivalents and restricted cash at end of period	4,157,000	3,400,000
Supplemental disclosures of cash flow information:
Cash paid for interest	177,000	667,000
Supplemental non-cash financing and investing information:
Recording of beneficial conversion feature on debt	2,313,000	7,200,000
Right-to-use asset acquired under operating lease	966,000
Conversion of debt to common stock	432,000
Fair value of amended convertible note issued in connection with the extinguishment of original convertible note	1,473,000
Transfer of equipment to inventories	44,000	172,000
Transfer of inventories to equipment	$ 22,000	$ 420,000

Note 1 - Description of Busines

Note 1 - Description of Business, Going Concern and Basis of Presentation	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Business Description and Basis of Presentation [Text Block]	1. Description of Business , Going C oncern and Basis of Presentation Organization and Basis of Presentation ThermoGenesis Holdings, Inc. (“ThermoGenesis Holdings,” the “Company,” “we,” “our,” “us”), formerly known as Cesca Therapeutics Inc., develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. The Company currently markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed CAR-TXpress™ platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. The Company was founded in 1986 The Company provides the AutoXpress ® For Clinical Bio-Banking Applications: ● AXP Automated Cell Separation System – an automated, fully closed cell separation system for isolating and retrieving stem and progenitor cells from umbilical cord blood. ● BioArchive Automated Cryopreservation System – an automated, robotic, liquid nitrogen controlled-rate-freezing and cryogenic storage system for cord blood samples and cell therapeutic products used in clinical applications. For Point-of-Care Applications: ● PXP For Large Scale Cell Processing and Biomanufacturing: ● X X ® X ® X ® X ● CAR-TXpress™ Platform – a modular designed, functionally closed platform that addresses the critical unmet need for large scale cellular processing and chemistry, manufacturing and controls (“CMC”) needs for manufacturing chimeric antigen receptor (“CAR”) T cell therapies. CAR-TXpress is owned and developed through a subsidiary in which we own 80% January 1, 2019, July 2017 20% third 20% 80% 100% In the reorganization, the Company reacquired the non-controlling interest shares in ThermoGenesis Corp., which had an accumulated deficit of $1,711,000, 20% $1,100,000. $2,843,000 ThermoGenesis Holdings is an affiliate of the Boyalife Group, a global diversified life science holding company that focuses on stem cell technology and cell-based therapeutics. Reverse Stock Split On June 4, 2019, one 1 ten 10 350,000,000 not All historical share amounts disclosed herein have been retroactively restated to reflect the reverse split and subsequent share exchange. No Liquidity and Going Concern The Company has a Revolving Credit Agreement (the “Credit Agreement”) with Boyalife Asset Holding II, Inc. ( See Note 5 December 31, 2019, $8,713,000 $10,000,000 may may no At December 31, 2019, $3,157,000 $3,176,000. December 31, 2019 $236,932,000. one The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern; however, the conditions described herein raise substantial doubt about the Company’s ability to do so. The consolidated financial statements do not may Principles of Consolidation The consolidated financial statements include the accounts of ThermoGenesis Holdings and its wholly-owned subsidiaries, ThermoGenesis Corp. and TotipotentRX Cell Therapy, Pvt. Ltd and ThermoGenesis Corp’s majority-owned subsidiary, CARTXpress Bio. All significant intercompany accounts and transactions have been eliminated upon consolidation. Non - controlling Interests The 20% not 80%

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]	2. Summary of Significant Accounting Policies Use of Estimates Preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates are used for, but not Revenue Recognition Revenue is recognized based on the five 606: Step 1 Step 2 not Step 3 Step 4 one Step 5 Device Sales Device sales include devices and consumables for BioArchive, AXP, not Service Revenue Service revenue principally consists of maintenance contracts for BioArchive, AXP and CAR-TXpress products. Devices sold have warranty periods of one two one three not Clinical Services Service revenue in our Clinical Development Segment includes point of care procedures and cord blood processing and storage. Point of care procedures are recognized when the procedures are performed. Cord blood processing and storage is recognized as the performance obligations are satisfied. Processing revenue is recognized when that performance obligation is completed immediately after the baby’s birth, with storage revenue recorded as deferred revenue and recognized ratably over time for up to 21 December 31, 2019 2018, $237,000 $252,000, December 31, 2019, $14,000 $223,000 December 31, 2018, $14,000 $238,000 may not 2019. 2019 The following table summarizes the revenues of the Company’s reportable segments for the year ended December 31, 2019: Year Ended December 31, 2019 Device Revenue Service Revenue Other Revenue Total Revenue Device Segment: AXP $ 7,313,000 $ 209,000 $ 7,522,000 BioArchive 1,472,000 1,438,000 2,910,000 Manual Disposables 909,000 -- 909,000 CAR-TXpress 1,457,000 13,000 $ 95,000 1,565,000 Other -- -- 51,000 51,000 Total Device Segment 11,151,000 1,660,000 146,000 12,957,000 Clinical Development Segment: Disposables 68,000 -- -- 68,000 Other -- 22,000 -- 22,000 Total Clinical Development 68,000 22,000 -- 90,000 Total $ 11,219,000 $ 1,682,000 $ 146,000 $ 13,047,000 The following table summarizes the revenues of the Company’s reportable segments for the year ended December 31, 2018: Year Ended December 31, 2018 Device Revenue Service Revenue Other Revenue Total Revenue Device Segment: AXP $ 4,131,000 $ 262,000 $ -- $ 4,393,000 BioArchive 1,792,000 1,306,000 -- 3,098,000 Manual Disposables 976,000 -- -- 976,000 CAR-TXpress 907,000 -- -- 907,000 Other -- -- 95,000 95,000 Total Device Segment 7,806,000 1,568,000 95,000 9,469,000 Clinical Development Segment: Bone Marrow -- 135,000 -- 135,000 Other 38,000 30,000 -- 68,000 Total Clinical Development 38,000 165,000 -- 203,000 Total $ 7,844,000 $ 1,733,000 $ 95,000 $ 9,672,000 In 2019, no no not may not Payments from domestic customers are normally due in two may 120 no Contract Balances Generally, all sales are contract sales (with either an underlying contract or purchase order). The Company does not December 31, 2019 $1,049,000. $620,000 $485,000 December 31, 2019 2018, $1,901,000 $303,000 December 31, 2019 2018, Exclusivity Fee On August 30, 2019, five two X ® $2,000,000 The Company performed an evaluation of the revenue recognition of the $2,000,000 606. $2,000,000 one two five seven seven December 31, 2019, $96,000 $2,000,000 $1,904,000 $286,000 $1,618,000 Backlog of Remaining Customer Performance Obligations The following table includes revenue expected to be recognized and recorded as sales in the future from the backlog of performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period. 2020 2021 2022 2023 2024 and beyond Total Service revenue $ 848,000 $ 632,000 $ 228,000 $ 90,000 $ 30,000 $ 1,828,000 Clinical revenue 14,000 14,000 $ 14,000 14,000 181,000 237,000 Exclusivity Fee 286,000 286,000 286,000 286,000 760,000 1,904,000 Total $ 1,148,000 $ 932,000 $ 528,000 $ 390,000 $ 971,000 $ 3,969,000 Revenues are net of normal discounts. Shipping and handling fees billed to customers are included in net revenues, while the related costs are included in cost of revenues. Cash and Cash Equivalents The Company considers all highly liquid investments with a maturity of three may $10,000 $11,000 December 31, 2019 2018 not Foreign Currency Translation The Company’s reporting currency is the US dollar. The functional currency of the Company’s subsidiaries in India is the Indian rupee (“INR”). Assets and liabilities are translated into US dollars at period end exchange rates. Revenue and expenses are translated at average rates of exchange prevailing during the periods presented. Cash flows are also translated at average exchange rates for the period, therefore, amounts reported on the consolidated statement of cash flows do not $15,000 $30,000 December 31, 2019 2018, Goodwill, Intangible Assets and Impairment Assessments Goodwill represents the excess of the purchase price in a business combination over the fair value of net tangible and intangible assets acquired. Intangible assets that are not three ten For goodwill and indefinite-lived intangible assets, the carrying amounts are periodically reviewed for impairment (at least annually) and whenever events or changes in circumstances indicate that the carrying value of these assets may not 350 ,”Intangibles-Goodwill and Other” not 50 Fair Value of Financial Instruments In accordance with ASC 820, Fair Value Measurements and Disclosures The guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors that market participants would use in valuing the asset or liability. The guidance establishes three may Level 1: Level 2: 1 not Level 3: The carrying values of cash and cash equivalents, accounts receivable and accounts payable approximate fair value due to their short duration. The fair value of the Company’s derivative obligation liability is classified as Level 3 3 Accounts Receivable and Allowance for Doubtful Accounts The Company’s receivables are recorded when billed and represent claims against third may Inventories Inventories are stated at the lower of cost or net realizable value and include the cost of material, labor and manufacturing overhead. Cost is determined on the first first not Because some of the Company’s products are highly dependent on government and third may may Equipment and Leasehold Improvements Equipment consisting of machinery and equipment, computers and software, office equipment and leasehold improvements is recorded at cost less accumulated depreciation. Repairs and maintenance costs are expensed as incurred. Depreciation for machinery and equipment, computers and software and office furniture is computed under the straight-line method over the estimated useful lives. Leasehold improvements are amortized under the straight-line method over their estimated useful lives or the remaining lease period, whichever is shorter. When equipment and leasehold improvements are sold or otherwise disposed of, the asset account and related accumulated depreciation account are relieved, and the impact of any resulting gain or loss is recognized within general and administrative expenses in the consolidated statement of operations for the period. Warranty We provide for the estimated cost of product warranties at the time revenue is recognized. While we engage in extensive product quality programs and processes, including actively monitoring and evaluating the quality of our component suppliers, our warranty obligation is affected by product failure rates, material usage and service delivery costs incurred in correcting a product failure. Should actual product failure rates, material usage or service delivery costs differ from our estimates, revisions to the estimated warranty liability could have a material impact on our financial position, cash flows or results of operations. Debt Discount and Issue Costs The Company amortizes debt discount and debt issue costs over the life of the associated debt instrument, using the straight-line method which approximates the interest rate method. Derivative Financial Instruments In connection with the sale of convertible debt and equity instruments, the Company may first Stock - Based Compensation We use the Black-Scholes-Merton option-pricing formula in determining the fair value of our options at the grant date and apply judgment in estimating the key assumptions that are critical to the model such as the expected term, volatility and forfeiture rate of an option. Our estimate of these key assumptions is based on historical information and judgment regarding market factors and trends. If any of the key assumptions change significantly, stock-based compensation expense for new awards may The Company has three Note 10 Valuation and Amortization Method – The Company estimates the fair value of stock options granted using the Black-Scholes-Merton option-pricing formula. This fair value is then amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period. The formula does not not Expected Term – For options which the Company has limited available data, the expected term of the option is based on the simplified method. This simplified method averages an award’s vesting term and its contractual term. For all other options, the Company's expected term represents the period that the Company's stock-based awards are expected to be outstanding and was determined based on historical experience of similar awards, giving consideration to the contractual terms of the stock-based awards, vesting schedules and expectations of future employee behavior. Expected Volatility – Expected volatility is based on historical volatility. Historical volatility is computed using daily pricing observations for recent periods that correspond to the expected term of the options. Expected Dividend – The Company has not not zero Risk-Free Interest Rate – The Company bases the risk-free interest rate used in the valuation method on the implied yield currently available on U.S. Treasury zero Estimated Forfeitures – When estimating forfeitures, the Company considers voluntary and involuntary termination behavior as well as analysis of actual option forfeitures. Research and Development Research and development costs, consisting of salaries and benefits, costs of disposables, facility costs, contracted services and stock-based compensation from the engineering, regulatory and scientific affairs departments, that are useful in developing and clinically testing new products, services, processes or techniques, as well as expenses for activities that may no Acquired In-Process Research and Development Acquired in-process research and development that the Company acquires through business combinations represents the fair value assigned to incomplete research projects which, at the time of acquisition, have not first not not Patent Costs The costs incurred in connection with patent applications, in defending and maintaining intellectual property rights and litigation proceedings are expensed as incurred. Credit Risk Currently, the Company primarily manufactures and sells cellular processing systems and thermodynamic devices principally to the blood and cellular component processing industry and performs ongoing evaluations of the credit worthiness of the Company’s customers. The Company believes that adequate provisions for uncollectible accounts have been made in the accompanying consolidated financial statements. To date, the Company has not Segment Reporting Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the Chief Operating Decision Maker (“CODM”), or decision-making group, whose function is to allocate resources to and assess the performance of the operating segments. The Company has identified its Chief Executive Officer as the CODM. In determining its reportable segments, the Company considered the markets and the products or services provided to those markets. The Company has two ● The Device Segment, engages in the development and commercialization of automated technologies for cell-based therapeutics and bio-processing. The device division is operated through the Company’s ThermoGenesis Corp. subsidiary. ● The Clinical Development Segment, is developing autologous (utilizing the patient’s own cells) stem cell-based therapeutics that address significant unmet medical needs for applications within the vascular, cardiology and orthopedic markets. Income Taxes The tax years 1999 2018 no no no The Company’s estimates of income taxes and the significant items resulting in the recognition of deferred tax assets and liabilities reflect the Company’s assessment of future tax consequences of transactions that have been reflected in the financial statements or tax returns for each taxing jurisdiction in which the Company operates. The Company bases the provision for income taxes on the Company’s current period results of operations, changes in deferred income tax assets and liabilities, income tax rates, and changes in estimates of uncertain tax positions in the jurisdictions in which the Company operates. The Company recognizes deferred tax assets and liabilities when there are temporary differences between the financial reporting basis and tax basis of assets and liabilities and for the expected benefits of using net operating loss and tax credit loss carryforwards. The Company establishes valuation allowances when necessary to reduce the carrying amount of deferred income tax assets to the amounts that the Company believes are more likely than not one may Income tax consequences that arise in connection with a business combination include identifying the tax basis of assets and liabilities acquired and any contingencies associated with uncertain tax positions assumed or resulting from the business combination. Deferred tax assets and liabilities related to temporary differences of an acquired entity are recorded as of the date of the business combination and are based on the Company’s estimate of the appropriate tax basis that will be accepted by the various taxing authorities and its determination as to whether any of the acquired deferred tax liabilities could be a source of taxable income to realize the Company’s pre-existing deferred tax assets. Net Loss per Share Net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding plus the pre-funded warrants. For the purpose of calculating basic net loss per share, the additional shares of common stock that are issuable upon exercise of the pre-funded warrants have been included since the shares are issuable for a negligible consideration and have no 324,445 December 31, 2019 December 31: Year Ended December 31, 2019 2018 Common stock equivalents of convertible promissory note and accrued interest 6,683,646 4,840,556 Vested Series A warrants 40,441 40,441 Unvested Series A warrants (1) 69,853 69,853 Warrants – other 1,281,327 1,616,227 Stock options 291,807 302,364 Total 8,367,074 6,869,441 ( 1 The unvested Series A warrants were subject to vesting based upon the amount of funds actually received by the Company in the second August 2015 February 2021. Reclassifications Certain prior period amounts have been reclassified to conform to the current period presentation. The reclassifications did not Recently Adopted Accounting Standards On January 1, 2018, No. 2014 09, Revenue from Contracts with Customers ( “ Topic 606 ” )” ( “ ASC606 ” ) not January 1, 2018. January 1, 2018 606, not 605” $79,000 January 1, 2018 606, 606 In June 2018, 2018 07, “Compensation-Stock Compensation ( “ Topic 718 ” ): Improvements to Nonemployee Share-Based Payment Accounting” 718 January 1, 2019. In February 2016, 2016 02 Leases January 1, 2019. The new standard requires lessees to recognize both the right-of-use assets and lease liabilities in the balance sheet for most leases, whereas under previous GAAP only finance lease liabilities (previously referred to as capital leases) were recognized in the balance sheet. In addition, the definition of a lease has been revised which may not The new standard provides a number of transition practical expedients, which the Company has elected, including: ● A “package of three” expedients that must be taken together and allow entities to ( 1 not 2 3 not ● An implementation expedient which allows the requirements of the standard in the period of adoption with no The impact of adoption did not January 1, 2019 one January 2019, five $966,000 no Recently Issued Accounting Standards In December 2019, 2019 12 Income Taxes (Topic 740 2019 12 740 December 15, 2020, In August 2018, 2018 13, Fair Value Measurement (“Topic 820” December 15, 2019, not In June 2016, ASU 2016 13, 326” 2016 13 December 15, 2022, not

Note 3 - Intangible Assets and

Note 3 - Intangible Assets and Goodwill	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Goodwill and Intangible Assets Disclosure [Text Block]	3. Intangible Assets and Goodwill U.S. GAAP requires that goodwill and intangible assets with indefinite lives be assessed annually for impairment. The Company completed its annual impairment test for 2019 fourth 3 no December 31, 2019. fourth may During the year ended December 31, 2018, June 30, 2018 2018. December 31, 2018. Intangible Assets Goodwill Balance at December 31, 2017, net $ 21,629,000 $ 13,976,000 Amortization and foreign exchange (152,000 ) -- Impairment loss (19,886,000 ) (13,195,000 ) Balance at December 31, 2018, net $ 1,591,000 $ 781,000 Amortization and foreign exchange (124,000 ) -- Balance at December 31, 2019, net $ 1,467,000 $ 781,000 Intangible assets consist of the following based on the Company’s determination of the fair value of identifiable assets acquired: As of December 31, 2019 Weighted Average Amortization Period (in Years) Gross Carrying Amount Accumulated Amortization Impairment Net Trade names 3 $ 53,000 $ 45,000 $ -- $ 8,000 Developed technology 10 318,000 79,000 -- 239,000 Licenses 7 437,000 367,000 -- 70,000 Device registration 7 66,000 66,000 -- -- Customer relationships 3 443,000 436,000 -- 7,000 Amortizable intangible assets 1,317,000 993,000 -- 324,000 In process technology 1,143,000 -- -- 1,143,000 Clinical protocols -- -- -- -- Total $ 2,460,000 $ 993,000 $ -- $ 1,467,000 As of December 31, 2018 Weighted Average Amortization Period (in Years) Gross Carrying Amount Accumulated Amortization Impairment Net Trade names 3 $ 54,000 $ 38,000 $ 16,000 Developed technology 10 318,000 48,000 270,000 Licenses 7 448,000 307,000 141,000 Device registration 7 84,000 68,000 $ 16,000 -- Customer relationships 3 451,000 430,000 -- 21,000 Amortizable intangible assets 1,355,000 891,000 16,000 448,000 In process technology 1,143,000 -- -- 1,143,000 Clinical protocols 19,870,000 -- 19,870,000 -- Total $ 22,368,000 $ 891,000 $ 19,886,000 $ 1,591,000 The change in the gross carrying amount is due to foreign currency exchange fluctuations and the write-off of assets for impairment. Amortization of intangible assets was $124,000 December 31, 2019 $131,000 December 31, 2018. not not not not December 31, 2018. Year Ended December 31, 2020 109,000 2021 40,000 2022 32,000 2023 32,000 2024 32,000 Thereafter 79,000 Total $ 324,000

Note 4 - Equipment and Leasehol

Note 4 - Equipment and Leasehold Improvements, Net	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	4. Equipment and Leasehold Improvements, Net Equipment and leasehold improvements consisted of the following: Year Ended December 31, 2019 2018 Estimated Useful Life (Years) Machinery and equipment $ 6,107,000 $ 6,136,000 2.5 - 10 Computer and software 631,000 664,000 2 - 5 Office equipment 256,000 264,000 5 - 10 Leasehold improvements 932,000 931,000 Shorter of 5 years or remaining lease term Total equipment 7,926,000 7,995,000 Less accumulated depreciation (5,898,000 ) (5,433,000 ) Total equipment and leasehold improvements, net $ 2,028,000 $ 2,562,000 Depreciation expense for the years ended December 31, 2019 2018 $574,000 $539,000,

Note 5 - Related Party Transact

Note 5 - Related Party Transactions	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	5. Related Party Transactions Healthbanks Biotech (USA) Inc. On November 26, 2019 80% 20% first 115% 2018 no $1,000,000 In December 2019, $3,000,000 600,000 $5.00 5.66% no 75.47% 18.87% 5.66% The Company initially determined that ImmuneCyte would be considered a variable interest entity, as a result of the significant influence the Company has over operations and its’ lack of sufficient equity at inception. After the additional investment of $3,000,000, no $28,000, For 2019, no $78,000. 18.87% $15,000. $3,000,000 $8,000 $14,000 $0 Convertible Promissory Note and Revolving Credit Agreement In March 2017, $10,000,000 March 6, 2022 ( $8,713,000 $7,200,000 December 31, 2019 2018, $1,287,000 may may no The Credit Agreement and the Convertible Promissory Note issued thereunder (the “Note”) provide that the principal and all accrued and unpaid interest under the Loan will be due and payable on the Maturity Date, with payments of interest-only due on the last day of each calendar year. The Loan bears interest at 22% five December 31, 2019, not not December 31, 2019. The Maturity Date of the Note is subject to acceleration at the option of the Lender upon customary events of default, which include; a breach of the Loan documents, termination of operations, or bankruptcy. The Lender’s obligation to make advances under the Loan is subject to the Company’s representations and warranties in the Credit Agreement continuing to be true at all times and there being no The Credit Agreement and Note were amended in April 2018. $16.10 two 2018, $1.80. It was concluded that the conversion option contained a beneficial conversion feature and as a result of the modifications to the conversion price, the Company recorded a debt discount in the amount of $7,200,000 2018 $1,513,000 March 31, 2019. $2,344,000 $1,174,000 December 31, 2019 2018, $1,869,000 $1,513,000 December 31, 2019 2018, Distributor Agreement On August 21, 2017, The term of the agreement is for three two Revenues During the year ended December 31, 2019, $794,000 $20,000 December 31, 2019. December 31, 2018, $665,000 $0 December 31, 2018. License Agreement On March 12, 2018, X Pursuant to the terms of the Agreement, ThermoGenesis Corp. has granted IncoCell an exclusive license to purchase and use, at a discounted purchase price, X ten may ninety 90 December 31, 2019 2018, $83,000 $14,000 $83,000 $14,000 December 31, 2019 2018,

Note 6 - Convertible Promissory

Note 6 - Convertible Promissory Note	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Debt Disclosure [Text Block]	6. Convertible Promissory Note On January 29, 2019, $800,000 “January 2019 six $1.80 2 90% $0.50 The January 2019 twenty-four 24% January 2019 eighteen 18 January 2019 January 2019 may On the date that is six January 2019 January 2019 January 2019 may January 2019 January 2019 4.99% 9.99% $800,000, May 30, 2019. The January 2019 January 2019 may January 2019 On July 23, 2019, No. 1 January 2019 January 2019 July 29, 2020 July 31, 2022. January 2019 January 2019 January 2019 10% January 2019 $840,000 December 31, 2019. $1,473,000 $556,000 December 31, 2019. $77,000 January 2019 December 31, 2019. Stock price at date of issuance $ 3.05 Exercise price (1) $ 1.80 Risk-free interest rate 1.8 % Expected dividend yield -- Expected term (in years) 3.02 Expected volatility 93 % ( 1 For the exercise price, the model inputs also accounted for the fair value protection under the Amended Note, which allows for the holder to convert at the lower of $1.80 90% $0.50 During the year ended December 31, 2019, $432,000 240,000 $60,000 December 31, 2019. On July 23, 2019, $1,000,000 “July 2019 six July 2019 $1.80 90% $0.50 July 2019 twenty-four 24% July 2019 three July 31, 2022. However, if stockholder approval of the conversion feature of the July 2019 not second 2020 fourteen The July 2019 may six July 2019 may July 2019 July 2019 On August 28, 2018, 100,000 $1.80 296,500 $1.70 one $0.10 $684,000 $623,000 $61,000. December 31, 2019, August 2018 February 26, 2019, not February 26, 2019.

Note 7 - Derivative Obligations

Note 7 - Derivative Obligations	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Derivatives and Fair Value [Text Block]	7. Derivative Obligations Series A Warrants Series A warrants to purchase 40,441 June 30, 2016. Year Ended December 31, 2019 2018 Market price of common stock $ 4.40 $ 2.70 Expected volatility 96 % 94 % Contractual term (years) 1.2 2.2 Discount rate 1.59 % 2.48 % Dividend rate 0 % 0 % Exercise price $ 80.00 $ 80.00 Expected volatilities are based on the historical volatility of the Company’s common stock. Contractual term is based on remaining term of the respective warrants. The discount rate represents the yield on U.S. Treasury bonds with a maturity equal to the contractual term. The Company recorded a gain (loss) of $1,000 December 31, 2019 $596,000 December 31, 2018, The following table represents the Company’s fair value hierarchy for its financial liabilities measured at fair value on a recurring basis as of December 31, 2019 2018: Year Ended December 31, Derivative Obligation 2019 2018 Balance $ - $ 1,000 Level 1 $ - $ - Level 2 $ - $ - Level 3 $ - $ 1,000 The following table reflects the change in fair value of the Company’s derivative liability: Amount Balance – December 31, 2017 $ 597,000 Change in fair value of derivative obligation (596,000 ) Balance – December 31, 2018 1,000 Change in fair value of derivative obligation (1,000 ) Balance – December 31, 2019 $ --

Note 8 - Commitments and Contin

Note 8 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	8. Commitments and Contingencies Financial Covenants Effective May 15, 2017, one not $2,000,000 $1,000,000 March 2020). December 31, 2019. Potential Severance Payments The Company’s Chief Executive Officer has rights upon termination under his employment agreement. With respect to his agreement at December 31, 2019, $2.3 Contingencies and Restricted Cash In fiscal 2016, May 4, 2017, $1,000,000 August 2016. October 2017, $1,000,000 June 26, 2018. September 24, 2018, July 22, 2019, February 2020 $1,000,000. no $1,000,000 $1,400,000 December 31, 2019. $1,000,000 $400,000 $1,000,000 In the normal course of operations, the Company may December 31, 2019, may not Warranty The Company offers a warranty on all its non-disposable products of one two Changes in the Company’s warranty reserve, which is included in other current liabilities in the accompanying consolidated balance sheet is as follows: Year Ended December 31, 2019 2018 Beginning balance $ 186,000 $ 291,000 Warranties originated during the year 254,000 199,000 Claims settled made during the year (154,000 ) (252,000 ) Changes in reserve estimate (9,000 ) (52,000 ) Ending balance $ 277,000 $ 186,000 Coronavirus (COVID- 19 In December 2019, 19 19 19 may

Note 9 - Leases

Note 9 - Leases	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	9 . Leases Operating Leases The Company leases the Rancho Cordova, California and Gurgaon, India facilities pursuant to operating leases. The Rancho Cordova lease expires in May 2024. September 2023; September 2019 three Operating lease assets and liabilities are recognized at the lease commencement date. Operating lease liabilities represent the present value of remaining minimum lease payments. Operating lease assets represent our right to use an underlying asset and are based upon the operating lease liabilities adjusted for prepayments or accrued lease payments, initial direct costs, lease incentives, and impairment of operating lease assets. To determine the present value of lease payments not The following summarizes the Company’s operating leases: December 31, 2019 Right-of-use operating lease assets, net $ 859,000 Current lease liability 118,000 Non-current lease liability 761,000 Weighted average remaining lease term 4.4 Discount rate 22 % Maturities of lease liabilities by calendar year for our operating leases are as follows: 2020 301,000 2021 310,000 2022 319,000 2023 328,000 2024 139,000 Thereafter -- Total lease payment $ 1,397,000 Less: imputed interest (538,000 ) Present value of operating lease liabilities $ 859,000 Statement of Cash Flows In January 2019, $966,000 $291,000 December 31, 2019. Operating Lease Costs Operating lease costs were $410,000 December 31, 2019, $204,000 $108,000 $72,000 $26,000 30 Finance Leases Finance leases are included in equipment and other current and non-current liabilities in the accompanying condensed consolidated balance sheet. The amortization and interest expense are included in general and administrative expense and interest expense, respectively in the accompanying statements of operations. These leases are not December 31, 2019.

Note 10 - Stockholders' Equity

Note 10 - Stockholders' Equity	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	10. Stockholders ’ Equity Common Stock On December 13, 2019, may $4.4 3 No. 333 235509 may 415 may not August 9, 2022. 3% December 31, 2019, 50,746 $280,000 $5.44 $113,000 $167,000. On April 18, 2019, “April 444,445 $1.70 one $0.10 $756,000. April April 26, 2019 April three sixty-five 365 December 31, 2019, 120,000 April 324,445 On August 28, 2018, 100,000 $1.80 296,500 $1.70 one $0.10 $623,000 $61,000. February 26, 2019, not February 26, 2019. December 31, 2019, 296,500 August 2018 On May 18, 2018, 647,501 269,167 $6.00 $5,473,000, $4,792,000 $679,000. one one one one one one one $6.00 five 269,167 May 2018 second 2018. On March 28, 2018, 60,964 $22.70 $171,000, $1,213,000. 30,482 $26.80 six September 28, 2018, 5.5 Warrants A summary of warrant activity is as follows: Year Ended December 31, 2019 2018 Number of Shares Weighted- Average Exercise Price Per Share Number of Shares Weighted- Average Exercise Price Per Share Beginning balance 1,726,522 $ 29.88 482,873 $ 93.70 Warrants granted 444,445 $ 0.10 1,512,816 $ 4.20 Warrants exercised (435,264 ) $ 0.35 (269,167 ) $ 0.10 Warrants expired/canceled (19,637 ) -- Outstanding 1,716,066 $ 25.23 1,726,522 $ 29.88 Exercisable 1,646,214 $ 22.91 1,656,668 $ 27.80 Equity Plans and Agreements The Amended 2016 2016 May 2017, 600,000 may June 22, 2018, 2016 may 1,325,000 May 30, 2019, 2016 may 1,325,000 3,925,000 December 31, 2019, 103,803 2016 The 2012 “2012 2,500 2012 100% not ten one December 31, 2019, 234 The 2006 “2006 2006 not 2016. December 31, 2019, 3,865 On December 29, 2017, 2017 280,000 December 29, 2017. 1,000,000 20,000 December 31, 2019. On April 7, 2019, two 800,000 $0.65 300,000 December 31, 2019. On December 14, 2018, 214,000 $2.979 five first four 169,934 2016 May 30, 2019. Stock Based Compensation The Company recorded stock-based compensation of $614,000 December 31, 2019 $652,000 December 31, 2018, Year Ended December 31, 2019 2018 Cost of revenues $ 3,000 $ 15,000 Sales and marketing 185,000 63,000 Research and development 98,000 136,000 General and administrative 328,000 438,000 $ 614,000 $ 652,000 Stock Options The Company issues new shares of common stock upon exercise of stock options. The following is a summary of option activity for the Company’s stock option plans: Number of Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life Aggregate Intrinsic Value Outstanding at January 1, 2019 302,368 $ 13.99 Granted 11,450 $ 4.38 Forfeited/cancelled (22,011 ) $ 9.42 Outstanding at December 31, 2019 291,807 $ 13.96 8.3 $ 280,000 Vested and Expected to Vest at December 31, 2019 224,102 $ 15.72 8.2 $ 203,000 Exercisable at December 31, 2019 147,124 $ 19.79 7.9 $ 115,000 The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted price of the Company’s common stock. There were no December 31, 2019 2018. Non-vested stock option activity for the year ended December 31, 2019, Non-vested Stock Options Weighted-Average Grant Date Fair Value Outstanding at January 1, 2019 212,172 $6.39 Granted 11,450 $3.30 Vested (63,675 ) $6.73 Cancelled/forfeited (15,264 ) $2.74 Outstanding at December 31, 2019 144,683 $6.38 The fair value of the Company’s stock options granted for the year ended December 31, 2019 December 31, 2018 Year Ended December 31, 2019 2018 Expected life (years) 5 6 Risk-free interest rate 1.68 % 2.7 % Expected volatility 103 % 103 % Dividend yield 0 % 0 % The weighted average grant date fair value of options granted during the years ended December 31, 2019 2018 $3.30 $3.20 At December 31, 2019, not $1,051,000. three December 31, 2019 December 31, 2018 $428,000 $633,000

Note 11 - Concentrations

Note 11 - Concentrations	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Concentration Risk Disclosure [Text Block]	1 1 . Concentrations One customer had an accounts receivable balance of $337,000 26% $494,000 33% December 31, 2019 2018, $3,575,000 28% $2,120,000 22% December 31, 2019 2018, $177,000 14% $229,000 15% December 31, 2019 2018, $1,470,000 11% $861,000 9% December 31, 2019 2018, second $170,000 13% $220,000 15% December 31, 2019 2018, Two suppliers accounted for 57% 18% December 31, 2019. 43% 14% December 31, 2018. The Company has a contract manufacturer in Costa Rica that produces certain disposables. The Company’s equipment and leasehold improvements, net of accumulated depreciation, is summarized below by geographic area: Year Ended December 31, 2019 2018 United States $ 1,108,000 $ 1,614,000 Costa Rica 582,000 601,000 India 225,000 211,000 All other countries 113,000 136,000 Total equipment, net $ 2,028,000 $ 2,562,000

Note 12 - Segment Reporting

Note 12 - Segment Reporting	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	1 2 . Segment Reporting The Company has two The Device Segment, engages in the development and commercialization of automated technologies for cell-based therapeutics and bio-processing. The device division is operated through the Company’s ThermoGenesis Corp. subsidiary. The Clinical Development Segment, utilizes autologous (utilizing the patient’s own cells) stem cell-based therapeutics through the Company’s TotipotentRX subsidiary in Gurgaon, India. The following table summarizes the operating results of the Company’s reportable segments: Year Ended December 31, 2019 Device Clinical Development Total Net revenues $ 12,957,000 $ 90,000 $ 13,047,000 Cost of revenues 7,175,000 176,000 7,351,000 Gross profit 5,782,000 (86,000 ) 5,696,000 Operating expenses 7,081,000 3,348,000 10,429,000 Operating loss $ (1,299,000 ) $ (3,434,000 ) $ (4,733,000 ) Depreciation and amortization $ 530,000 $ 275,000 $ 805,000 Stock-based compensation expense $ 393,000 $ 221,000 $ 614,000 Goodwill $ 781,000 $ -- $ 781,000 Total assets $ 13,420,000 $ 1,794,000 $ 15,214,000 Year Ended December 31, 2018 Device Clinical Development Total Net revenues $ 9,469,000 $ 203,000 $ 9,672,000 Cost of revenues 7,205,000 274,000 7,479,000 Gross profit 2,264,000 (71,000 ) 2,193,000 Operating expenses 8,398,000 37,340,000 45,738,000 Operating loss $ (6,134,000 ) $ (37,411,000 ) $ (43,545,000 ) Depreciation and amortization $ 398,000 $ 272,000 $ 670,000 Stock-based compensation expense $ 179,000 $ 473,000 $ 652,000 Goodwill $ 781,000 -- $ 781,000 Total assets $ 10,815,000 $ 3,796,000 $ 14,611,000 The Company had sales in the following geographical areas for the: Year Ended December 31, 2019 2018 United States $ 6,787,000 $ 4,854,000 Asia – other 2,108,000 1,717,000 Europe 1,233,000 1,165,000 China 2,346,000 1,143,000 Other 573,000 793,000 $ 13,047,000 $ 9,672,000 The Company attributes revenue to different geographic areas based on where items are shipped, or services are performed.

Note 13 - Income Taxes

Note 13 - Income Taxes	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Income Tax Disclosure [Text Block]	1 3 . Income Taxes Loss before income tax benefits was comprised of $9,934,000 $150,000 December 31, 2019 $45,458,000 $212,000 December 31, 2018. The reconciliation of federal income tax attributable to operations computed at the federal statutory tax rate to income tax benefit is as follows for the: Year Ended December 31, 2019 2018 Statutory federal income tax benefit $ (2,118,000 ) $ (9,591,000 ) Intangible assets 673,000 3,119,000 Change in valuation allowance (681,000 ) (2,084,000 ) Expiration of net operating losses 1,187,000 1,271,000 United States tax reform rate change -- -- Disallowed financing costs 1,119,000 240,000 State and local taxes (205,000 ) 2,344,000 Other 25,000 (29,000 ) Total income tax benefit $ -- $ (4,730,000 ) For the year ended December 31, 2019, no $4,730,000 December 31, 2018. 2019 December 31, 2018 At December 31, 2019, $121,195,000 $109,293,000 2037 $11,902,000 $43,870,000 may 2039. $2,495,000 may 2027. At December 31, 2019, $1,591,000 2020 2039, $1,476,000 not Significant components of the Company’s deferred tax assets and liabilities for federal and state income taxes are as follows: Year Ended December 31, 2019 2018 Deferred tax assets: Net operating loss carryforwards $ 26,758,000 $ 27,312,000 Income tax credit carryforwards 2,757,000 2,769,000 Stock compensation 384,000 850,000 Lease Obligation 185,000 -- Deferred Revenue 419,000 -- Other 943,000 1,027,000 Total deferred tax assets 31,446,000 31,958,000 Deferred tax liabilities Indefinite lived intangible assets -- -- Depreciation and amortization (408,000 ) (419,000 ) Lease asset (180,000 ) -- Total deferred tax liabilities (588,000 ) (419,000 ) Valuation allowance (30,858,000 ) (31,539,000 ) Net deferred taxes $ -- $ -- ASC 740 not." not The valuation allowance decreased by $681,000 $2,266,000 December 31, 2019 2018, The transition tax is based on total post- 1986 December 31, 2019, not no not not In August 2016, 1986. may 2016 2016 2019.

Note 14 - Employee Retirement P

Note 14 - Employee Retirement Plan	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Pension and Other Postretirement Benefits Disclosure [Text Block]	1 4 . Employee Retirement Plan The Company sponsors an Employee Retirement Plan, generally available to all employees, in accordance with Section 401 may may no December 31, 2019 December 31, 2018.

Note 15 - Subsequent Events

Note 15 - Subsequent Events	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Subsequent Events [Text Block]	1 5 . Subsequent Events The Company has evaluated events subsequent to the balance sheet date for inclusion in the accompanying consolidated financial statements through the date of issuance and determined that no On February 13, 2020, $3,000,000 April 16, 2018. December 31, 2019 $1,869,000 $1,131,000 1,666,670 $1.80 $7,582,000. On March 17, 2020, #1 March 16, 2020 ( May 15, 2017 may, $2,000,000 $1,000,000 one thirty 30

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Use of Estimates, Policy [Policy Text Block]	Use of Estimates Preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates are used for, but not
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents The Company considers all highly liquid investments with a maturity of three may $10,000 $11,000 December 31, 2019 2018 not
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currency Translation The Company’s reporting currency is the US dollar. The functional currency of the Company’s subsidiaries in India is the Indian rupee (“INR”). Assets and liabilities are translated into US dollars at period end exchange rates. Revenue and expenses are translated at average rates of exchange prevailing during the periods presented. Cash flows are also translated at average exchange rates for the period, therefore, amounts reported on the consolidated statement of cash flows do not $15,000 $30,000 December 31, 2019 2018,
Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]	Goodwill, Intangible Assets and Impairment Assessments Goodwill represents the excess of the purchase price in a business combination over the fair value of net tangible and intangible assets acquired. Intangible assets that are not three ten For goodwill and indefinite-lived intangible assets, the carrying amounts are periodically reviewed for impairment (at least annually) and whenever events or changes in circumstances indicate that the carrying value of these assets may not 350 ,”Intangibles-Goodwill and Other” not 50
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments In accordance with ASC 820, Fair Value Measurements and Disclosures The guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors that market participants would use in valuing the asset or liability. The guidance establishes three may Level 1: Level 2: 1 not Level 3: The carrying values of cash and cash equivalents, accounts receivable and accounts payable approximate fair value due to their short duration. The fair value of the Company’s derivative obligation liability is classified as Level 3 3
Receivable [Policy Text Block]	Accounts Receivable and Allowance for Doubtful Accounts The Company’s receivables are recorded when billed and represent claims against third may
Inventory, Policy [Policy Text Block]	Inventories Inventories are stated at the lower of cost or net realizable value and include the cost of material, labor and manufacturing overhead. Cost is determined on the first first not Because some of the Company’s products are highly dependent on government and third may may
Property, Plant and Equipment, Policy [Policy Text Block]	Equipment and Leasehold Improvements Equipment consisting of machinery and equipment, computers and software, office equipment and leasehold improvements is recorded at cost less accumulated depreciation. Repairs and maintenance costs are expensed as incurred. Depreciation for machinery and equipment, computers and software and office furniture is computed under the straight-line method over the estimated useful lives. Leasehold improvements are amortized under the straight-line method over their estimated useful lives or the remaining lease period, whichever is shorter. When equipment and leasehold improvements are sold or otherwise disposed of, the asset account and related accumulated depreciation account are relieved, and the impact of any resulting gain or loss is recognized within general and administrative expenses in the consolidated statement of operations for the period.
Standard Product Warranty, Policy [Policy Text Block]	Warranty We provide for the estimated cost of product warranties at the time revenue is recognized. While we engage in extensive product quality programs and processes, including actively monitoring and evaluating the quality of our component suppliers, our warranty obligation is affected by product failure rates, material usage and service delivery costs incurred in correcting a product failure. Should actual product failure rates, material usage or service delivery costs differ from our estimates, revisions to the estimated warranty liability could have a material impact on our financial position, cash flows or results of operations.
Debt, Policy [Policy Text Block]	Debt Discount and Issue Costs The Company amortizes debt discount and debt issue costs over the life of the associated debt instrument, using the straight-line method which approximates the interest rate method.
Derivatives, Policy [Policy Text Block]	Derivative Financial Instruments In connection with the sale of convertible debt and equity instruments, the Company may first
Share-based Payment Arrangement [Policy Text Block]	Stock - Based Compensation We use the Black-Scholes-Merton option-pricing formula in determining the fair value of our options at the grant date and apply judgment in estimating the key assumptions that are critical to the model such as the expected term, volatility and forfeiture rate of an option. Our estimate of these key assumptions is based on historical information and judgment regarding market factors and trends. If any of the key assumptions change significantly, stock-based compensation expense for new awards may The Company has three Note 10 Valuation and Amortization Method – The Company estimates the fair value of stock options granted using the Black-Scholes-Merton option-pricing formula. This fair value is then amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period. The formula does not not Expected Term – For options which the Company has limited available data, the expected term of the option is based on the simplified method. This simplified method averages an award’s vesting term and its contractual term. For all other options, the Company's expected term represents the period that the Company's stock-based awards are expected to be outstanding and was determined based on historical experience of similar awards, giving consideration to the contractual terms of the stock-based awards, vesting schedules and expectations of future employee behavior. Expected Volatility – Expected volatility is based on historical volatility. Historical volatility is computed using daily pricing observations for recent periods that correspond to the expected term of the options. Expected Dividend – The Company has not not zero Risk-Free Interest Rate – The Company bases the risk-free interest rate used in the valuation method on the implied yield currently available on U.S. Treasury zero Estimated Forfeitures – When estimating forfeitures, the Company considers voluntary and involuntary termination behavior as well as analysis of actual option forfeitures.
Research and Development Expense, Policy [Policy Text Block]	Research and Development Research and development costs, consisting of salaries and benefits, costs of disposables, facility costs, contracted services and stock-based compensation from the engineering, regulatory and scientific affairs departments, that are useful in developing and clinically testing new products, services, processes or techniques, as well as expenses for activities that may no
Business Combinations Policy [Policy Text Block]	Acquired In-Process Research and Development Acquired in-process research and development that the Company acquires through business combinations represents the fair value assigned to incomplete research projects which, at the time of acquisition, have not first not not
Legal Costs, Policy [Policy Text Block]	Patent Costs The costs incurred in connection with patent applications, in defending and maintaining intellectual property rights and litigation proceedings are expensed as incurred.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Credit Risk Currently, the Company primarily manufactures and sells cellular processing systems and thermodynamic devices principally to the blood and cellular component processing industry and performs ongoing evaluations of the credit worthiness of the Company’s customers. The Company believes that adequate provisions for uncollectible accounts have been made in the accompanying consolidated financial statements. To date, the Company has not
Segment Reporting, Policy [Policy Text Block]	Segment Reporting Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the Chief Operating Decision Maker (“CODM”), or decision-making group, whose function is to allocate resources to and assess the performance of the operating segments. The Company has identified its Chief Executive Officer as the CODM. In determining its reportable segments, the Company considered the markets and the products or services provided to those markets. The Company has two ● The Device Segment, engages in the development and commercialization of automated technologies for cell-based therapeutics and bio-processing. The device division is operated through the Company’s ThermoGenesis Corp. subsidiary. ● The Clinical Development Segment, is developing autologous (utilizing the patient’s own cells) stem cell-based therapeutics that address significant unmet medical needs for applications within the vascular, cardiology and orthopedic markets.
Income Tax, Policy [Policy Text Block]	Income Taxes The tax years 1999 2018 no no no The Company’s estimates of income taxes and the significant items resulting in the recognition of deferred tax assets and liabilities reflect the Company’s assessment of future tax consequences of transactions that have been reflected in the financial statements or tax returns for each taxing jurisdiction in which the Company operates. The Company bases the provision for income taxes on the Company’s current period results of operations, changes in deferred income tax assets and liabilities, income tax rates, and changes in estimates of uncertain tax positions in the jurisdictions in which the Company operates. The Company recognizes deferred tax assets and liabilities when there are temporary differences between the financial reporting basis and tax basis of assets and liabilities and for the expected benefits of using net operating loss and tax credit loss carryforwards. The Company establishes valuation allowances when necessary to reduce the carrying amount of deferred income tax assets to the amounts that the Company believes are more likely than not one may Income tax consequences that arise in connection with a business combination include identifying the tax basis of assets and liabilities acquired and any contingencies associated with uncertain tax positions assumed or resulting from the business combination. Deferred tax assets and liabilities related to temporary differences of an acquired entity are recorded as of the date of the business combination and are based on the Company’s estimate of the appropriate tax basis that will be accepted by the various taxing authorities and its determination as to whether any of the acquired deferred tax liabilities could be a source of taxable income to realize the Company’s pre-existing deferred tax assets.
Earnings Per Share, Policy [Policy Text Block]	Net Loss per Share Net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding plus the pre-funded warrants. For the purpose of calculating basic net loss per share, the additional shares of common stock that are issuable upon exercise of the pre-funded warrants have been included since the shares are issuable for a negligible consideration and have no 324,445 December 31, 2019 December 31: Year Ended December 31, 2019 2018 Common stock equivalents of convertible promissory note and accrued interest 6,683,646 4,840,556 Vested Series A warrants 40,441 40,441 Unvested Series A warrants (1) 69,853 69,853 Warrants – other 1,281,327 1,616,227 Stock options 291,807 302,364 Total 8,367,074 6,869,441 ( 1 The unvested Series A warrants were subject to vesting based upon the amount of funds actually received by the Company in the second August 2015 February 2021.
Reclassification, Policy [Policy Text Block]	Reclassifications Certain prior period amounts have been reclassified to conform to the current period presentation. The reclassifications did not
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition Revenue is recognized based on the five 606: Step 1 Step 2 not Step 3 Step 4 one Step 5 Device Sales Device sales include devices and consumables for BioArchive, AXP, not Service Revenue Service revenue principally consists of maintenance contracts for BioArchive, AXP and CAR-TXpress products. Devices sold have warranty periods of one two one three not Clinical Services Service revenue in our Clinical Development Segment includes point of care procedures and cord blood processing and storage. Point of care procedures are recognized when the procedures are performed. Cord blood processing and storage is recognized as the performance obligations are satisfied. Processing revenue is recognized when that performance obligation is completed immediately after the baby’s birth, with storage revenue recorded as deferred revenue and recognized ratably over time for up to 21 December 31, 2019 2018, $237,000 $252,000, December 31, 2019, $14,000 $223,000 December 31, 2018, $14,000 $238,000 may not 2019. 2019 The following table summarizes the revenues of the Company’s reportable segments for the year ended December 31, 2019: Year Ended December 31, 2019 Device Revenue Service Revenue Other Revenue Total Revenue Device Segment: AXP $ 7,313,000 $ 209,000 $ 7,522,000 BioArchive 1,472,000 1,438,000 2,910,000 Manual Disposables 909,000 -- 909,000 CAR-TXpress 1,457,000 13,000 $ 95,000 1,565,000 Other -- -- 51,000 51,000 Total Device Segment 11,151,000 1,660,000 146,000 12,957,000 Clinical Development Segment: Disposables 68,000 -- -- 68,000 Other -- 22,000 -- 22,000 Total Clinical Development 68,000 22,000 -- 90,000 Total $ 11,219,000 $ 1,682,000 $ 146,000 $ 13,047,000 The following table summarizes the revenues of the Company’s reportable segments for the year ended December 31, 2018: Year Ended December 31, 2018 Device Revenue Service Revenue Other Revenue Total Revenue Device Segment: AXP $ 4,131,000 $ 262,000 $ -- $ 4,393,000 BioArchive 1,792,000 1,306,000 -- 3,098,000 Manual Disposables 976,000 -- -- 976,000 CAR-TXpress 907,000 -- -- 907,000 Other -- -- 95,000 95,000 Total Device Segment 7,806,000 1,568,000 95,000 9,469,000 Clinical Development Segment: Bone Marrow -- 135,000 -- 135,000 Other 38,000 30,000 -- 68,000 Total Clinical Development 38,000 165,000 -- 203,000 Total $ 7,844,000 $ 1,733,000 $ 95,000 $ 9,672,000 In 2019, no no not may not Payments from domestic customers are normally due in two may 120 no Contract Balances Generally, all sales are contract sales (with either an underlying contract or purchase order). The Company does not December 31, 2019 $1,049,000. $620,000 $485,000 December 31, 2019 2018, $1,901,000 $303,000 December 31, 2019 2018, Exclusivity Fee On August 30, 2019, five two X ® $2,000,000 The Company performed an evaluation of the revenue recognition of the $2,000,000 606. $2,000,000 one two five seven seven December 31, 2019, $96,000 $2,000,000 $1,904,000 $286,000 $1,618,000 Backlog of Remaining Customer Performance Obligations The following table includes revenue expected to be recognized and recorded as sales in the future from the backlog of performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period. 2020 2021 2022 2023 2024 and beyond Total Service revenue $ 848,000 $ 632,000 $ 228,000 $ 90,000 $ 30,000 $ 1,828,000 Clinical revenue 14,000 14,000 $ 14,000 14,000 181,000 237,000 Exclusivity Fee 286,000 286,000 286,000 286,000 760,000 1,904,000 Total $ 1,148,000 $ 932,000 $ 528,000 $ 390,000 $ 971,000 $ 3,969,000 Revenues are net of normal discounts. Shipping and handling fees billed to customers are included in net revenues, while the related costs are included in cost of revenues.
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Adopted Accounting Standards On January 1, 2018, No. 2014 09, Revenue from Contracts with Customers ( “ Topic 606 ” )” ( “ ASC606 ” ) not January 1, 2018. January 1, 2018 606, not 605” $79,000 January 1, 2018 606, 606 In June 2018, 2018 07, “Compensation-Stock Compensation ( “ Topic 718 ” ): Improvements to Nonemployee Share-Based Payment Accounting” 718 January 1, 2019. In February 2016, 2016 02 Leases January 1, 2019. The new standard requires lessees to recognize both the right-of-use assets and lease liabilities in the balance sheet for most leases, whereas under previous GAAP only finance lease liabilities (previously referred to as capital leases) were recognized in the balance sheet. In addition, the definition of a lease has been revised which may not The new standard provides a number of transition practical expedients, which the Company has elected, including: ● A “package of three” expedients that must be taken together and allow entities to ( 1 not 2 3 not ● An implementation expedient which allows the requirements of the standard in the period of adoption with no The impact of adoption did not January 1, 2019 one January 2019, five $966,000 no Recently Issued Accounting Standards In December 2019, 2019 12 Income Taxes (Topic 740 2019 12 740 December 15, 2020, In August 2018, 2018 13, Fair Value Measurement (“Topic 820” December 15, 2019, not In June 2016, ASU 2016 13, 326” 2016 13 December 15, 2022, not

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Disaggregation of Revenue [Table Text Block]	Year Ended December 31, 2019 Device Revenue Service Revenue Other Revenue Total Revenue Device Segment: AXP $ 7,313,000 $ 209,000 $ 7,522,000 BioArchive 1,472,000 1,438,000 2,910,000 Manual Disposables 909,000 -- 909,000 CAR-TXpress 1,457,000 13,000 $ 95,000 1,565,000 Other -- -- 51,000 51,000 Total Device Segment 11,151,000 1,660,000 146,000 12,957,000 Clinical Development Segment: Disposables 68,000 -- -- 68,000 Other -- 22,000 -- 22,000 Total Clinical Development 68,000 22,000 -- 90,000 Total $ 11,219,000 $ 1,682,000 $ 146,000 $ 13,047,000 Year Ended December 31, 2018 Device Revenue Service Revenue Other Revenue Total Revenue Device Segment: AXP $ 4,131,000 $ 262,000 $ -- $ 4,393,000 BioArchive 1,792,000 1,306,000 -- 3,098,000 Manual Disposables 976,000 -- -- 976,000 CAR-TXpress 907,000 -- -- 907,000 Other -- -- 95,000 95,000 Total Device Segment 7,806,000 1,568,000 95,000 9,469,000 Clinical Development Segment: Bone Marrow -- 135,000 -- 135,000 Other 38,000 30,000 -- 68,000 Total Clinical Development 38,000 165,000 -- 203,000 Total $ 7,844,000 $ 1,733,000 $ 95,000 $ 9,672,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block]	2020 2021 2022 2023 2024 and beyond Total Service revenue $ 848,000 $ 632,000 $ 228,000 $ 90,000 $ 30,000 $ 1,828,000 Clinical revenue 14,000 14,000 $ 14,000 14,000 181,000 237,000 Exclusivity Fee 286,000 286,000 286,000 286,000 760,000 1,904,000 Total $ 1,148,000 $ 932,000 $ 528,000 $ 390,000 $ 971,000 $ 3,969,000
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Year Ended December 31, 2019 2018 Common stock equivalents of convertible promissory note and accrued interest 6,683,646 4,840,556 Vested Series A warrants 40,441 40,441 Unvested Series A warrants (1) 69,853 69,853 Warrants – other 1,281,327 1,616,227 Stock options 291,807 302,364 Total 8,367,074 6,869,441

Note 3 - Intangible Assets an_2

Note 3 - Intangible Assets and Goodwill (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Schedule of Intangible Assets and Goodwill [Table Text Block]	Intangible Assets Goodwill Balance at December 31, 2017, net $ 21,629,000 $ 13,976,000 Amortization and foreign exchange (152,000 ) -- Impairment loss (19,886,000 ) (13,195,000 ) Balance at December 31, 2018, net $ 1,591,000 $ 781,000 Amortization and foreign exchange (124,000 ) -- Balance at December 31, 2019, net $ 1,467,000 $ 781,000
Schedule of Finite-Lived Intangible Assets [Table Text Block]	As of December 31, 2019 Weighted Average Amortization Period (in Years) Gross Carrying Amount Accumulated Amortization Impairment Net Trade names 3 $ 53,000 $ 45,000 $ -- $ 8,000 Developed technology 10 318,000 79,000 -- 239,000 Licenses 7 437,000 367,000 -- 70,000 Device registration 7 66,000 66,000 -- -- Customer relationships 3 443,000 436,000 -- 7,000 Amortizable intangible assets 1,317,000 993,000 -- 324,000 In process technology 1,143,000 -- -- 1,143,000 Clinical protocols -- -- -- -- Total $ 2,460,000 $ 993,000 $ -- $ 1,467,000 As of December 31, 2018 Weighted Average Amortization Period (in Years) Gross Carrying Amount Accumulated Amortization Impairment Net Trade names 3 $ 54,000 $ 38,000 $ 16,000 Developed technology 10 318,000 48,000 270,000 Licenses 7 448,000 307,000 141,000 Device registration 7 84,000 68,000 $ 16,000 -- Customer relationships 3 451,000 430,000 -- 21,000 Amortizable intangible assets 1,355,000 891,000 16,000 448,000 In process technology 1,143,000 -- -- 1,143,000 Clinical protocols 19,870,000 -- 19,870,000 -- Total $ 22,368,000 $ 891,000 $ 19,886,000 $ 1,591,000
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Year Ended December 31, 2020 109,000 2021 40,000 2022 32,000 2023 32,000 2024 32,000 Thereafter 79,000 Total $ 324,000

Note 4 - Equipment and Leaseh_2

Note 4 - Equipment and Leasehold Improvements, Net (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Property, Plant and Equipment [Table Text Block]	Year Ended December 31, 2019 2018 Estimated Useful Life (Years) Machinery and equipment $ 6,107,000 $ 6,136,000 2.5 - 10 Computer and software 631,000 664,000 2 - 5 Office equipment 256,000 264,000 5 - 10 Leasehold improvements 932,000 931,000 Shorter of 5 years or remaining lease term Total equipment 7,926,000 7,995,000 Less accumulated depreciation (5,898,000 ) (5,433,000 ) Total equipment and leasehold improvements, net $ 2,028,000 $ 2,562,000

Note 6 - Convertible Promisso_2

Note 6 - Convertible Promissory Note (Tables)	12 Months Ended
	Dec. 31, 2019
Convertible Debt [Member]
Notes Tables
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	Stock price at date of issuance $ 3.05 Exercise price (1) $ 1.80 Risk-free interest rate 1.8 % Expected dividend yield -- Expected term (in years) 3.02 Expected volatility 93 %

Note 7 - Derivative Obligatio_2

Note 7 - Derivative Obligations (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]	Year Ended December 31, Derivative Obligation 2019 2018 Balance $ - $ 1,000 Level 1 $ - $ - Level 2 $ - $ - Level 3 $ - $ 1,000
Derivative Instruments, Gain (Loss) [Table Text Block]	Amount Balance – December 31, 2017 $ 597,000 Change in fair value of derivative obligation (596,000 ) Balance – December 31, 2018 1,000 Change in fair value of derivative obligation (1,000 ) Balance – December 31, 2019 $ --
Series A Warrant [Member]
Notes Tables
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	Year Ended December 31, 2019 2018 Market price of common stock $ 4.40 $ 2.70 Expected volatility 96 % 94 % Contractual term (years) 1.2 2.2 Discount rate 1.59 % 2.48 % Dividend rate 0 % 0 % Exercise price $ 80.00 $ 80.00

Note 8 - Commitments and Cont_2

Note 8 - Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Schedule of Product Warranty Liability [Table Text Block]	Year Ended December 31, 2019 2018 Beginning balance $ 186,000 $ 291,000 Warranties originated during the year 254,000 199,000 Claims settled made during the year (154,000 ) (252,000 ) Changes in reserve estimate (9,000 ) (52,000 ) Ending balance $ 277,000 $ 186,000

Note 9 - Leases (Tables)

Note 9 - Leases (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Lease, Cost [Table Text Block]	December 31, 2019 Right-of-use operating lease assets, net $ 859,000 Current lease liability 118,000 Non-current lease liability 761,000 Weighted average remaining lease term 4.4 Discount rate 22 %
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	2020 301,000 2021 310,000 2022 319,000 2023 328,000 2024 139,000 Thereafter -- Total lease payment $ 1,397,000 Less: imputed interest (538,000 ) Present value of operating lease liabilities $ 859,000

Note 10 - Stockholders' Equity

Note 10 - Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Year Ended December 31, 2019 2018 Number of Shares Weighted- Average Exercise Price Per Share Number of Shares Weighted- Average Exercise Price Per Share Beginning balance 1,726,522 $ 29.88 482,873 $ 93.70 Warrants granted 444,445 $ 0.10 1,512,816 $ 4.20 Warrants exercised (435,264 ) $ 0.35 (269,167 ) $ 0.10 Warrants expired/canceled (19,637 ) -- Outstanding 1,716,066 $ 25.23 1,726,522 $ 29.88 Exercisable 1,646,214 $ 22.91 1,656,668 $ 27.80
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Year Ended December 31, 2019 2018 Cost of revenues $ 3,000 $ 15,000 Sales and marketing 185,000 63,000 Research and development 98,000 136,000 General and administrative 328,000 438,000 $ 614,000 $ 652,000
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Number of Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life Aggregate Intrinsic Value Outstanding at January 1, 2019 302,368 $ 13.99 Granted 11,450 $ 4.38 Forfeited/cancelled (22,011 ) $ 9.42 Outstanding at December 31, 2019 291,807 $ 13.96 8.3 $ 280,000 Vested and Expected to Vest at December 31, 2019 224,102 $ 15.72 8.2 $ 203,000 Exercisable at December 31, 2019 147,124 $ 19.79 7.9 $ 115,000
Non Vested Stock Options Activity [Table Text Block]	Non-vested Stock Options Weighted-Average Grant Date Fair Value Outstanding at January 1, 2019 212,172 $6.39 Granted 11,450 $3.30 Vested (63,675 ) $6.73 Cancelled/forfeited (15,264 ) $2.74 Outstanding at December 31, 2019 144,683 $6.38
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Year Ended December 31, 2019 2018 Expected life (years) 5 6 Risk-free interest rate 1.68 % 2.7 % Expected volatility 103 % 103 % Dividend yield 0 % 0 %

Note 11 - Concentrations (Table

Note 11 - Concentrations (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Schedule of Disclosure on Geographic Areas, Long-Lived Assets in Individual Foreign Countries by Country [Table Text Block]	Year Ended December 31, 2019 2018 United States $ 1,108,000 $ 1,614,000 Costa Rica 582,000 601,000 India 225,000 211,000 All other countries 113,000 136,000 Total equipment, net $ 2,028,000 $ 2,562,000

Note 12 - Segment Reporting (Ta

Note 12 - Segment Reporting (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Reconciliation of Revenue from Segments to Consolidated [Table Text Block]	Year Ended December 31, 2019 Device Clinical Development Total Net revenues $ 12,957,000 $ 90,000 $ 13,047,000 Cost of revenues 7,175,000 176,000 7,351,000 Gross profit 5,782,000 (86,000 ) 5,696,000 Operating expenses 7,081,000 3,348,000 10,429,000 Operating loss $ (1,299,000 ) $ (3,434,000 ) $ (4,733,000 ) Depreciation and amortization $ 530,000 $ 275,000 $ 805,000 Stock-based compensation expense $ 393,000 $ 221,000 $ 614,000 Goodwill $ 781,000 $ -- $ 781,000 Total assets $ 13,420,000 $ 1,794,000 $ 15,214,000 Year Ended December 31, 2018 Device Clinical Development Total Net revenues $ 9,469,000 $ 203,000 $ 9,672,000 Cost of revenues 7,205,000 274,000 7,479,000 Gross profit 2,264,000 (71,000 ) 2,193,000 Operating expenses 8,398,000 37,340,000 45,738,000 Operating loss $ (6,134,000 ) $ (37,411,000 ) $ (43,545,000 ) Depreciation and amortization $ 398,000 $ 272,000 $ 670,000 Stock-based compensation expense $ 179,000 $ 473,000 $ 652,000 Goodwill $ 781,000 -- $ 781,000 Total assets $ 10,815,000 $ 3,796,000 $ 14,611,000
Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]	Year Ended December 31, 2019 2018 United States $ 6,787,000 $ 4,854,000 Asia – other 2,108,000 1,717,000 Europe 1,233,000 1,165,000 China 2,346,000 1,143,000 Other 573,000 793,000 $ 13,047,000 $ 9,672,000

Note 13 - Income Taxes (Tables)

Note 13 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	Year Ended December 31, 2019 2018 Statutory federal income tax benefit $ (2,118,000 ) $ (9,591,000 ) Intangible assets 673,000 3,119,000 Change in valuation allowance (681,000 ) (2,084,000 ) Expiration of net operating losses 1,187,000 1,271,000 United States tax reform rate change -- -- Disallowed financing costs 1,119,000 240,000 State and local taxes (205,000 ) 2,344,000 Other 25,000 (29,000 ) Total income tax benefit $ -- $ (4,730,000 )
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	Year Ended December 31, 2019 2018 Deferred tax assets: Net operating loss carryforwards $ 26,758,000 $ 27,312,000 Income tax credit carryforwards 2,757,000 2,769,000 Stock compensation 384,000 850,000 Lease Obligation 185,000 -- Deferred Revenue 419,000 -- Other 943,000 1,027,000 Total deferred tax assets 31,446,000 31,958,000 Deferred tax liabilities Indefinite lived intangible assets -- -- Depreciation and amortization (408,000 ) (419,000 ) Lease asset (180,000 ) -- Total deferred tax liabilities (588,000 ) (419,000 ) Valuation allowance (30,858,000 ) (31,539,000 ) Net deferred taxes $ -- $ --

Note 1 - Description of Busin_2

Note 1 - Description of Business, Going Concern and Basis of Presentation (Details Textual)	Jun. 04, 2019	Jan. 01, 2019USD ($)	Dec. 31, 2019USD ($)shares	Jun. 30, 2019shares	Dec. 31, 2018USD ($)shares	Mar. 31, 2017USD ($)
Stockholders' Equity Attributable to Noncontrolling Interest, Ending Balance			$ 530,000		$ (1,711,000)
Reorganization of Subsidiary and Related Change in Non-controlling Interest
Common Stock, Shares Authorized | shares			350,000,000	350,000,000	350,000,000
Cash and Cash Equivalents, at Carrying Value, Ending Balance			$ 3,157,000		$ 2,400,000
Working Capital			3,176,000
Retained Earnings (Accumulated Deficit), Ending Balance			(236,932,000)		$ (227,435,000)
Boyalife Investment Fund II, Inc. [Member] | Revolving Credit Facility [Member]
Long-term Line of Credit, Total			8,713,000
Line of Credit Facility, Maximum Borrowing Capacity			10,000,000			$ 10,000,000
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	10
Noncontrolling Interest [Member]
Reorganization of Subsidiary and Related Change in Non-controlling Interest		$ 2,843,000	$ 2,843,000
CAR-TXpress [Member]
Noncontrolling Interest, Ownership Percentage by Parent		80.00%	80.00%
Minority Interest Acquired Through Exchange		20.00%
Stockholders' Equity Attributable to Noncontrolling Interest, Ending Balance		$ 1,100,000
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners			20.00%
ThermoGenesis [Member]
Noncontrolling Interest, Ownership Percentage by Parent		100.00%
Ownership in Subsidiary Exchanged		20.00%
Stockholders' Equity Attributable to Noncontrolling Interest, Ending Balance		$ (1,711,000)

Note 2 - Summary of Significa_3

Note 2 - Summary of Significant Accounting Policies (Details Textual)	Aug. 30, 2019USD ($)	Dec. 31, 2019USD ($)shares	Dec. 31, 2018USD ($)shares	Jan. 01, 2019USD ($)	Jan. 01, 2018USD ($)
Maximum Period Of Agreement		21 years
Deferred Revenue, Total		$ 1,049,000
Deferred Revenue, Current, Total		620,000	$ 485,000
Deferred Revenue, Noncurrent, Total		1,901,000	303,000
Cash and Cash Equivalents, at Carrying Value, Ending Balance		3,157,000	2,400,000
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total		15,000	$ 30,000
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments		$ 0
Number of Reportable Segments		2
Income Tax Examination, Penalties and Interest Accrued, Total		$ 0
Unrecognized Tax Benefits, Ending Balance		$ 0
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares		8,367,074	6,869,441
Operating Lease, Right-of-Use Asset		$ 859,000
Operating Lease, Liability, Total		859,000
Accounting Standards Update 2016-02 [Member]
Operating Lease, Right-of-Use Asset				$ 966,000
Operating Lease, Liability, Total				$ 966,000
Retained Earnings [Member]
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total
Retained Earnings [Member] | Accounting Standards Update 2014-09 [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption					$ (79,000)
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares		324,445
Minimum [Member]
Finite-Lived Intangible Asset, Useful Life		3 years
Maximum [Member]
Finite-Lived Intangible Asset, Useful Life		10 years
INDIA
Cash and Cash Equivalents, at Carrying Value, Ending Balance		$ 10,000	11,000
Supply Agreement [Member]
Contract with Customer, Liability, Total	$ 2,000,000
Supply Agreement, Term	5 years	7 years
Supply Agreement, Renewal Term	2 years	2 years
Proceeds from Customers		$ 2,000,000
Cord Blood Storage Revenue [Member]
Contract with Customer, Liability, Total		237,000	252,000
Contract with Customer, Liability, Current		14,000	14,000
Contract with Customer, Liability, Noncurrent		223,000	$ 238,000
Exclusivity Fee [Member]
Deferred Revenue, Total		1,904,000
Deferred Revenue, Current, Total		286,000
Deferred Revenue, Noncurrent, Total		1,618,000
Contract with Customer, Liability, Revenue Recognized		$ 96,000

Note 2 - Summary of Significa_4

Note 2 - Summary of Significant Accounting Policies - Revenues (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Net revenues	$ 13,047,000	$ 9,672,000
Device [Member]
Net revenues	12,957,000	9,469,000
Device [Member] | AXP [Member]
Net revenues	7,522,000	4,393,000
Device [Member] | BioArchive [Member]
Net revenues	2,910,000	3,098,000
Device [Member] | Manual Disposables [Member]
Net revenues	909,000	976,000
Device [Member] | CAR-TXpress [Member]
Net revenues	1,565,000	907,000
Device [Member] | Other Subsegments [Member]
Net revenues	51,000	95,000
Clinical Development [Member]
Net revenues	90,000	203,000
Clinical Development [Member] | Manual Disposables [Member]
Net revenues	68,000
Clinical Development [Member] | Other Subsegments [Member]
Net revenues	22,000	68,000
Clinical Development [Member] | Bone Marrow [Member]
Net revenues		135,000
Device Revenue [Member]
Net revenues	11,219,000	7,844,000
Device Revenue [Member] | Device [Member]
Net revenues	11,151,000	7,806,000
Device Revenue [Member] | Device [Member] | AXP [Member]
Net revenues	7,313,000	4,131,000
Device Revenue [Member] | Device [Member] | BioArchive [Member]
Net revenues	1,472,000	1,792,000
Device Revenue [Member] | Device [Member] | Manual Disposables [Member]
Net revenues	909,000	976,000
Device Revenue [Member] | Device [Member] | CAR-TXpress [Member]
Net revenues	1,457,000	907,000
Device Revenue [Member] | Device [Member] | Other Subsegments [Member]
Net revenues
Device Revenue [Member] | Clinical Development [Member]
Net revenues	68,000	38,000
Device Revenue [Member] | Clinical Development [Member] | Manual Disposables [Member]
Net revenues	68,000
Device Revenue [Member] | Clinical Development [Member] | Other Subsegments [Member]
Net revenues		38,000
Device Revenue [Member] | Clinical Development [Member] | Bone Marrow [Member]
Net revenues
Service [Member]
Net revenues	1,682,000	1,733,000
Service [Member] | Device [Member]
Net revenues	1,660,000	1,568,000
Service [Member] | Device [Member] | AXP [Member]
Net revenues	209,000	262,000
Service [Member] | Device [Member] | BioArchive [Member]
Net revenues	1,438,000	1,306,000
Service [Member] | Device [Member] | Manual Disposables [Member]
Net revenues
Service [Member] | Device [Member] | CAR-TXpress [Member]
Net revenues	13,000
Service [Member] | Device [Member] | Other Subsegments [Member]
Net revenues
Service [Member] | Clinical Development [Member]
Net revenues	22,000	165,000
Service [Member] | Clinical Development [Member] | Manual Disposables [Member]
Net revenues
Service [Member] | Clinical Development [Member] | Other Subsegments [Member]
Net revenues	22,000	30,000
Service [Member] | Clinical Development [Member] | Bone Marrow [Member]
Net revenues		135,000
Other [Member]
Net revenues	146,000	95,000
Other [Member] | Device [Member]
Net revenues	146,000	95,000
Other [Member] | Device [Member] | AXP [Member]
Net revenues
Other [Member] | Device [Member] | BioArchive [Member]
Net revenues
Other [Member] | Device [Member] | Manual Disposables [Member]
Net revenues
Other [Member] | Device [Member] | CAR-TXpress [Member]
Net revenues	95,000
Other [Member] | Device [Member] | Other Subsegments [Member]
Net revenues	51,000	95,000
Other [Member] | Clinical Development [Member]
Net revenues
Other [Member] | Clinical Development [Member] | Manual Disposables [Member]
Net revenues
Other [Member] | Clinical Development [Member] | Other Subsegments [Member]
Net revenues
Other [Member] | Clinical Development [Member] | Bone Marrow [Member]
Net revenues

Note 2 - Summary of Significa_5

Note 2 - Summary of Significant Accounting Policies - Remaining Performance Obligations (Details)	Dec. 31, 2019USD ($)
Revenue, Remaining Performance Obligation, Amount	$ 3,969,000
Service [Member]
Revenue, Remaining Performance Obligation, Amount	1,828,000
Clinical Revenue [Member]
Revenue, Remaining Performance Obligation, Amount	237,000
Exclusivity Fee [Member]
Revenue, Remaining Performance Obligation, Amount	$ 1,904,000

Note 2 - Summary of Significa_6

Note 2 - Summary of Significant Accounting Policies - Remaining Performance Obligations 2 (Details)	Dec. 31, 2019USD ($)
Revenue, Remaining Performance Obligation, Amount	$ 3,969,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 1,148,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 932,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 528,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 390,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 971,000
Service [Member]
Revenue, Remaining Performance Obligation, Amount	$ 1,828,000
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 848,000
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 632,000
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 228,000
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 90,000
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 30,000
Clinical Revenue [Member]
Revenue, Remaining Performance Obligation, Amount	$ 237,000
Clinical Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 14,000
Clinical Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 14,000
Clinical Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 14,000
Clinical Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 14,000
Clinical Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 181,000
Exclusivity Fee [Member]
Revenue, Remaining Performance Obligation, Amount	$ 1,904,000
Exclusivity Fee [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 286,000
Exclusivity Fee [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 286,000
Exclusivity Fee [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 286,000
Exclusivity Fee [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 286,000
Exclusivity Fee [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 760,000

Note 2 - Summary of Significa_7

Note 2 - Summary of Significant Accounting Policies - Anti-dilutive Securities (Details) - shares		12 Months Ended
		Dec. 31, 2019	Dec. 31, 2018
Anti-dilutive securities (in shares)		8,367,074	6,869,441
Convertible Debt Securities [Member]
Anti-dilutive securities (in shares)		6,683,646	4,840,556
Vested Series A Warrants [Member]
Anti-dilutive securities (in shares)		40,441	40,441
Unvested Series A Warrants [Member]
Anti-dilutive securities (in shares)	[1]	69,853	69,853
Warrant, Other [Member]
Anti-dilutive securities (in shares)		1,281,327	1,616,227
Share-based Payment Arrangement, Option [Member]
Anti-dilutive securities (in shares)		291,807	302,364
[1]	The unvested Series A warrants were subject to vesting based upon the amount of funds actually received by the Company in the second close of the August 2015 financing which never occurred. The warrants will remain outstanding but unvested until they expire in February 2021.

Note 3 - Intangible Assets an_3

Note 3 - Intangible Assets and Goodwill (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Amortization of Intangible Assets, Total	$ 124,000	$ 131,000

Note 3 - Intangible Assets an_4

Note 3 - Intangible Assets and Goodwill - Goodwill and Intangible Assets (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Intangible assets, net	$ 1,591,000	$ 21,629,000
Goodwill	781,000	13,976,000
Intangible assets, amortization and foreign exchange	(124,000)	(152,000)
Goodwill, foreign exchange
Intangible assets, impairment loss		(19,886,000)
Goodwill, impairment loss		(13,195,000)
Intangible assets, net	1,467,000	1,591,000
Goodwill	$ 781,000	$ 781,000

Note 3 - Intangible Assets an_5

Note 3 - Intangible Assets and Goodwill - Summary of Intangible Assets (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Gross Carrying Amount	$ 1,317,000	$ 1,355,000
Accumulated Amortization	993,000	891,000
Net	324,000	448,000
Impairment		16,000
Gross Carrying Amount	2,460,000	22,368,000
Impairment		19,886,000
Net	1,467,000	1,591,000	$ 21,629,000
In Process Techonology [Member]
Gross Carrying Amount	1,143,000	1,143,000
Impairment
Net	1,143,000	1,143,000
Clinical Protocols [Member]
Gross Carrying Amount		19,870,000
Impairment		19,870,000
Net
Trade Names [Member]
Weighted Average Amortization Period (Year)	3 years	3 years
Gross Carrying Amount	$ 53,000	$ 54,000
Accumulated Amortization	45,000	38,000
Net	$ 8,000	$ 16,000
Developed Technology Rights [Member]
Weighted Average Amortization Period (Year)	10 years	10 years
Gross Carrying Amount	$ 318,000	$ 318,000
Accumulated Amortization	79,000	48,000
Net	$ 239,000	$ 270,000
Licensing Agreements [Member]
Weighted Average Amortization Period (Year)	7 years	7 years
Gross Carrying Amount	$ 437,000	$ 448,000
Accumulated Amortization	367,000	307,000
Net	$ 70,000	$ 141,000
Device Registration [Member]
Weighted Average Amortization Period (Year)	7 years	7 years
Gross Carrying Amount	$ 66,000	$ 84,000
Accumulated Amortization	66,000	68,000
Net
Impairment		$ 16,000
Customer Relationships [Member]
Weighted Average Amortization Period (Year)	3 years	3 years
Gross Carrying Amount	$ 443,000	$ 451,000
Accumulated Amortization	436,000	430,000
Net	7,000	21,000
Impairment

Note 3 - Intangible Assets an_6

Note 3 - Intangible Assets and Goodwill - Future Amortization Expense (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
2020	$ 109,000
2021	40,000
2022	32,000
2023	32,000
2024	32,000
Thereafter	79,000
Total	$ 324,000	$ 448,000

Note 4 - Equipment and Leaseh_3

Note 4 - Equipment and Leasehold Improvements, Net (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Depreciation, Total	$ 574,000	$ 539,000

Note 4 - Equipment and Leaseh_4

Note 4 - Equipment and Leasehold Improvements, Net - Summary of Property, Plant, and Equipment (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Property, Plant, and Equipment, Gross	$ 7,926,000	$ 7,995,000
Less accumulated depreciation	(5,898,000)	(5,433,000)
Total equipment and leasehold improvements, net	2,028,000	2,562,000
Machinery and Equipment [Member]
Property, Plant, and Equipment, Gross	$ 6,107,000	6,136,000
Machinery and Equipment [Member] | Minimum [Member]
Estimated Useful Life (Year)	2 years 182 days
Machinery and Equipment [Member] | Maximum [Member]
Estimated Useful Life (Year)	10 years
Computer and Software [Member]
Property, Plant, and Equipment, Gross	$ 631,000	664,000
Computer and Software [Member] | Minimum [Member]
Estimated Useful Life (Year)	2 years
Computer and Software [Member] | Maximum [Member]
Estimated Useful Life (Year)	5 years
Office Equipment [Member]
Property, Plant, and Equipment, Gross	$ 256,000	264,000
Office Equipment [Member] | Minimum [Member]
Estimated Useful Life (Year)	5 years
Office Equipment [Member] | Maximum [Member]
Estimated Useful Life (Year)	10 years
Leasehold Improvements [Member]
Property, Plant, and Equipment, Gross	$ 932,000	$ 931,000
Leasehold Improvements, Estimated Useful Life	Shorter of 5 years or remaining lease term

Note 5 - Related Party Transa_2

Note 5 - Related Party Transactions (Details Textual) - USD ($)	Mar. 28, 2018	Mar. 12, 2018	Aug. 21, 2017	Dec. 31, 2019	Dec. 31, 2019	Dec. 31, 2018	Nov. 26, 2019	Mar. 31, 2019	Apr. 16, 2018	Apr. 01, 2018	Mar. 31, 2017
Stock Issued During Period, Shares, New Issues	60,964
Shares Issued, Price Per Share	$ 22.70
Revenue from Contract with Customer, Including Assessed Tax					$ 12,160,000	$ 9,003,000
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total					(10,099,000)	(40,940,000)
Income (Loss) from Equity Method Investments, Total					(15,000)
Assets, Current, Total				$ 9,861,000	9,861,000	8,626,000
Liabilities, Current, Total				6,685,000	6,685,000	6,365,000
Amortization of Debt Discount (Premium)					2,349,000	1,174,000
Revenue from Related Parties					887,000	669,000
Gross Profit, Total					5,696,000	$ 2,193,000
Adjustments for New Accounting Principle, Early Adoption [Member] | Accounting Standards Update 2017-11 [Member]
Debt Instrument, Unamortized Discount, Total								$ 1,513,000		$ 7,200,000
Boyalife Investment Fund II, Inc. [Member] | Convertible Debt [Member]
Debt Instrument, Convertible, Conversion Price						$ 1.80			$ 16.10
Boyalife Investment Fund II, Inc. [Member] | Revolving Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity				10,000,000	10,000,000						$ 10,000,000
Proceeds from Long-term Lines of Credit					8,713,000	$ 7,200,000
Line of Credit Facility, Remaining Borrowing Capacity				$ 1,287,000	$ 1,287,000
Debt Instrument, Interest Rate, Stated Percentage				22.00%	22.00%
Amortization of Debt Discount (Premium)					$ 2,344,000	1,174,000
Interest Payable				$ 1,869,000	1,869,000	1,513,000
Boyalife W.S.N. [Member]
Distributor Agreement Term			3 years
Distributor Agreement, Renewal Term			2 years
Revenue from Related Parties					794,000	665,000
Accounts Receivable, Related Parties				20,000	20,000	0
IncoCell [Member]
Revenue from Related Parties					83,000	14,000
Accounts Receivable, Related Parties				83,000	$ 83,000	$ 14,000
Contract Development Revenue, Term		10 years
ImmuneCyte [Member]
Proceeds from Issuance of Common Stock				$ 3,000,000
ImmuneCyte [Member] | Common Class A [Member]
Stock Issued During Period, Shares, New Issues				600,000
Shares Issued, Price Per Share				$ 5	$ 5
ImmuneCyte [Member]
Equity Method Investment, Ownership Percentage				18.87%	18.87%		20.00%
Joint Venture Purchase, Percent of Company's Cost							115.00%
Line of Credit Facility, Maximum Borrowing Capacity							$ 1,000,000
Equity Method Investment, Aggregate Cost							$ 28,000
Revenue from Contract with Customer, Including Assessed Tax					$ 0
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total					(78,000)
Income (Loss) from Equity Method Investments, Total					(15,000)
Assets, Current, Total				$ 3,000,000	3,000,000
Assets, Noncurrent, Total				8,000	8,000
Liabilities, Current, Total				14,000	14,000
Liabilities, Noncurrent, Total				$ 0	0
Gross Profit, Total					$ 0
ImmuneCyte [Member] | HealthBanks Biotech [Member]
Equity Method Investment, Ownership Percentage				75.47%	75.47%		80.00%
ImmuneCyte [Member] | Private Institution [Member]
Equity Method Investment, Ownership Percentage				5.66%	5.66%

Note 6 - Convertible Promisso_3

Note 6 - Convertible Promissory Note (Details Textual) - USD ($)	Jul. 23, 2019	Jan. 29, 2019	Aug. 28, 2018	May 18, 2018	Mar. 28, 2018	Dec. 31, 2019	Dec. 31, 2018	May 30, 2019
Gain (Loss) on Extinguishment of Debt, Total						$ (840,000)
Amortization of Debt Discount (Premium)						$ 2,349,000	$ 1,174,000
Stock Issued During Period, Shares, New Issues					60,964
Shares Issued, Price Per Share					$ 22.70
Class of Warrant or Right, Issued During Period						444,445	1,512,816
Payments of Stock Issuance Costs				$ 679,000	$ 171,000
Private Placement [Member]
Stock Issued During Period, Shares, New Issues			100,000
Shares Issued, Price Per Share			$ 1.80
Class of Warrant or Right, Issued During Period			296,500
Warrants Issued, Price Per Warrant			$ 1.70
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right			1
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 0.10
Proceeds from Issuance of Private Placement			$ 684,000
Proceeds from Issuance of Private Placement, Net			623,000
Payments of Stock Issuance Costs			$ 61,000
Convertible Debt [Member] | Notes [Member]
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger		90.00%
Debt Instrument, Interest Rate, Stated Percentage		24.00%
Debt Instrument, Term		1 year 180 days
Debt Instrument, Convertible, First Customary Conversion Blockers		4.99%
Debt Instrument, Convertible, Second customary conversion blockers		9.99%
Debt Instrument, Unamortized Discount, Total								$ 800,000
Convertible Debt [Member] | Notes [Member] | Maximum [Member]
Debt Instrument, Face Amount		$ 800,000
Debt Instrument, Convertible, Conversion Price		$ 1.80
Convertible Debt [Member] | Notes [Member] | Minimum [Member]
Debt Instrument, Convertible, Conversion Price		$ 0.50
Convertible Debt [Member] | January 2019 Notes, Amendment No. 1 [Member]
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger	90.00%
Debt Instrument, Unamortized Discount, Total						$ 556,000
Gain (Loss) on Extinguishment of Debt, Total						840,000
Long-term Debt, Fair Value	$ 1,473,000
Amortization of Debt Discount (Premium)						77,000
Debt Conversion, Original Debt, Amount						$ 432,000
Debt Conversion, Converted Instrument, Shares Issued						240,000
Interest Income (Expense), Net, Total						$ 60,000
Convertible Debt [Member] | January 2019 Notes, Amendment No. 1 [Member] | Maximum [Member]
Debt Instrument, Convertible, Conversion Price	$ 1.80
Convertible Debt [Member] | January 2019 Notes, Amendment No. 1 [Member] | Minimum [Member]
Debt Instrument, Convertible, Conversion Price	$ 0.50
Convertible Debt [Member] | The July 2019 Note [Member]
Debt Instrument, Face Amount	$ 1,000,000
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger	90.00%
Debt Instrument, Interest Rate, Stated Percentage	24.00%
Convertible Debt [Member] | The July 2019 Note [Member] | Maximum [Member]
Debt Instrument, Convertible, Conversion Price	$ 1.80
Convertible Debt [Member] | The July 2019 Note [Member] | Minimum [Member]
Debt Instrument, Convertible, Conversion Price	$ 0.50

Note 6 - Convertible Promisso_4

Note 6 - Convertible Promissory Note - Assumptions (Details) - Convertible Debt [Member]	Jul. 23, 2019
Measurement Input, Share Price [Member]
Long-term Debt, Measurement Input	3.05
Measurement Input, Exercise Price [Member]
Long-term Debt, Measurement Input	1.8	[1]
Measurement Input, Risk Free Interest Rate [Member]
Long-term Debt, Measurement Input	0.018
Measurement Input, Expected Dividend Rate [Member]
Long-term Debt, Measurement Input
Measurement Input, Expected Term [Member]
Long-term Debt, Measurement Input	3.02
Measurement Input, Price Volatility [Member]
Long-term Debt, Measurement Input	0.93
[1]	For the exercise price, the model inputs also accounted for the fair value protection under the Amended Note, which allows for the holder to convert at the lower of $1.80 share or 90% of the listed price of the stock on the day of conversion, whichever is lower (subject to a floor of $0.50).

Note 7 - Derivative Obligatio_3

Note 7 - Derivative Obligations (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Jun. 30, 2016
Class of Warrant or Right, Outstanding	1,716,066	1,726,522	482,873
Derivative, Gain (Loss) on Derivative, Net, Total	$ 1,000	$ 596,000
Series A Warrant [Member]
Class of Warrant or Right, Outstanding				40,441

Note 7 - Derivative Obligatio_4

Note 7 - Derivative Obligations - Fair Value Assumptions (Details) - Series A Warrant [Member]	Dec. 31, 2019	Dec. 31, 2018
Measurement Input, Share Price [Member]
Valuation assumption	4.4	2.7
Measurement Input, Price Volatility [Member]
Valuation assumption	0.96	0.94
Measurement Input, Expected Term [Member]
Valuation assumption	1.2	2.2
Measurement Input, Discount Rate [Member]
Valuation assumption	0.0159	0.0248
Measurement Input, Expected Dividend Rate [Member]
Valuation assumption	0	0
Measurement Input, Exercise Price [Member]
Valuation assumption	80	80

Note 7 - Derivative Obligatio_5

Note 7 - Derivative Obligations - Fair Value Hierarchy (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Derivative obligations		$ 1,000	$ 597,000
Fair Value, Recurring [Member]
Derivative obligations		1,000
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Derivative obligations
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Derivative obligations
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Derivative obligations		$ 1,000

Note 7 - Derivative Obligatio_6

Note 7 - Derivative Obligations - Change in Fair Value of Derivative Liabilities (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Balance	$ 1,000	$ 597,000
Change in fair value of derivative obligation	(1,000)	(596,000)
Balance		$ 1,000

Note 8 - Commitments and Cont_3

Note 8 - Commitments and Contingencies (Details Textual) - USD ($)	May 15, 2017	May 04, 2017	Feb. 29, 2020	Oct. 31, 2017	Dec. 31, 2019	Mar. 17, 2020
Payment Terms, Severance Compensation	1 year
Short Term Investment Minimum	$ 2,000,000
Minimum [Member]
Period Of Warranty On Products					1 year
Maximum [Member]
Period Of Warranty On Products					2 years
Subsequent Event [Member]
Short Term Investment Minimum						$ 1,000,000
Potential Severance Cost for Chief Operating Officer [Member]
Loss Contingency, Estimate of Possible Loss					$ 2,300,000
Litigation Related to Strategic Advisory Services [Member]
Loss Contingency, Damages Sought, Value		$ 1,000,000
Loss Contingency, Negotiation Condition Bond				$ 1,000,000
Litigation Related to Strategic Advisory Services [Member] | Subsequent Event [Member]
Loss Contingency, Damages Awarded, Value			$ 1,000,000
Gain (Loss) Related to Litigation Settlement, Total			(1,400,000)
Litigation Settlement, Expense			1,000,000
Litigation Settlement Interest			$ 400,000

Note 8 - Commitments and Cont_4

Note 8 - Commitments and Contingencies - Changes in Product Liability Included in Accrued Liabilities (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Beginning balance	$ 186,000	$ 291,000
Warranties originated during the year	254,000	199,000
Claims settled made during the year	(154,000)	(252,000)
Changes in reserve estimate	(9,000)	(52,000)
Ending balance	$ 277,000	$ 186,000

Note 9 - Leases (Details Textua

Note 9 - Leases (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2019	Jan. 01, 2019	Dec. 31, 2018
Operating Lease, Right-of-Use Asset	$ 859,000
Operating Lease, Payments	291,000
Operating Lease, Cost	410,000
Operating Lease, Interest Expense	204,000
Operating Lease, Right-of-Use Asset, Amortization	108,000
Variable Lease, Cost	72,000
Short-term Lease, Cost	$ 26,000
Accounting Standards Update 2016-02 [Member]
Operating Lease, Right-of-Use Asset		$ 966,000

Note 9 - Leases - Lease Informa

Note 9 - Leases - Lease Information (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Right-of-use operating lease assets, net	$ 859,000
Non-current lease liability	$ 761,000
Weighted average remaining lease term (Year)	4 years 146 days
Discount rate	22.00%
Current Liabilities [Member]
Current lease liability	$ 118,000

Note 9 - Leases - Maturities of

Note 9 - Leases - Maturities of Lease Liabilities (Details)	Dec. 31, 2019USD ($)
2020	$ 301,000
2021	310,000
2022	319,000
2023	328,000
2024	139,000
Thereafter
Total lease payment	1,397,000
Less: imputed interest	(538,000)
Present value of operating lease liabilities	$ 859,000

Note 10 - Stockholders' Equit_2

Note 10 - Stockholders' Equity (Details Textual) - USD ($)	Dec. 13, 2019	Apr. 18, 2019	Apr. 07, 2019	Dec. 14, 2018	Aug. 28, 2018	May 18, 2018	Mar. 28, 2018	Mar. 19, 2020	Jun. 30, 2018	Dec. 31, 2019	Dec. 31, 2018	May 30, 2019	Jun. 22, 2018	Dec. 31, 2017	May 05, 2017
Stock Issued During Period, Shares, New Issues							60,964
Proceeds from Issuance of Common Stock, Net							$ 1,213,000			$ 756,000	$ 6,629,000
Payments of Stock Issuance Costs						$ 679,000	$ 171,000
Class of Warrant or Right, Issued During Period										444,445	1,512,816
Class of Warrant or Right, Exercised During Period										435,264	269,167
Class of Warrant or Right, Outstanding										1,716,066	1,726,522			482,873
Shares Issued, Price Per Share							$ 22.70
Units Issued, Price per Unit						$ 6
Proceeds from Issuance or Sale of Equity, Total						$ 5,473,000
Proceeds from Issuance or Sale of Equity, Net						$ 4,792,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance										291,807	302,368
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			800,000	214,000						11,450
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price			$ 0.65	$ 2.979						$ 4.38
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares										300,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Subject to Approval of Amendment Plan				169,934
Share-based Payment Arrangement, Expense										$ 614,000	$ 652,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period										0	0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value										$ 3.30	$ 3.20
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value										$ 428,000	$ 633,000
Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period				4 years
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount										$ 1,051,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition										3 years
Amended 2016 Plan [Member
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized												3,925,000	1,325,000		600,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant										103,803
Plan 2012 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized										2,500
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant										234
Plan 2012 [Member] | Share-based Payment Arrangement, Option [Member]
Options Prices In Terms Of Fair Market Value										100.00%
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period										10 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period										1 year
2006 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance										3,865
Equity Incentive Plan 2017 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized										1,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant										20,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross										280,000
Units [Member]
Number of Units Issued						647,501
Convertible Units, Number of Common Shares Called by Each Unit						1
Convertible Units, Number of Common Warrants Called by Each Unit						1
Pre-funded Units [member]
Number of Units Issued						269,167
Convertible Units, Number of Common Warrants Called by Each Unit						1
Convertible Units, Number of Pre-funded Warrants Called by Each Unit						1
April 2019 Pre-funded Warrants [Member]
Class of Warrant or Right, Issued During Period		444,445
Warrants Issued, Price Per Warrant		$ 1.70
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right		1
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.10
Proceeds from Issuance of Warrants		$ 756,000
Class of Warrant or Right, Exercised During Period										120,000
Class of Warrant or Right, Outstanding										324,445
Common Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 6
Warrants and Rights Outstanding, Term						5 years
Number of Units Exercised									269,167
Common Warrants [Member] | Units [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right						1
Common Warrants [Member] | Pre-funded Units [member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right						1
Pre-funded Warrant [Member] | Pre-funded Units [member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right						1
Warrants Issused in Private Placement [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 26.80
Warrants and Rights Outstanding, Term							5 years 182 days
Class of Warrant or Right, Number of Securities Called by Warrants or Rights							30,482
At The Market Offering Agreement [Member]
Maximum Offering Price for Issuance of Common Stock	$ 4,400,000
Commission as Percentage of Gross Proceeds	3.00%
At The Market Offering Agreement [Member] | Subsequent Event [Member]
Stock Issued During Period, Shares, New Issues								50,746
Proceeds from Issuance of Common Stock								$ 280,000
Shares Issued, Average Price Per Share								$ 5.44
Proceeds from Issuance of Common Stock, Net								$ 113,000
Payments of Stock Issuance Costs								$ 167,000
Private Placement [Member]
Stock Issued During Period, Shares, New Issues					100,000
Payments of Stock Issuance Costs					$ 61,000
Class of Warrant or Right, Issued During Period					296,500
Warrants Issued, Price Per Warrant					$ 1.70
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right					1
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 0.10
Class of Warrant or Right, Exercised During Period										296,500
Shares Issued, Price Per Share					$ 1.80
Proceeds from Issuance of Private Placement, Net					$ 623,000

Note 10 - Stockholders' Equit_3

Note 10 - Stockholders' Equity - Warrant Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Outstanding (in shares)	1,726,522	482,873
Outstanding, weighted average exercise price (in dollars per share)	$ 29.88	$ 93.70
Warrants granted (in shares)	444,445	1,512,816
Warrants granted, weighted average exercise price (in dollars per share)	$ 0.10	$ 4.20
Warrants exercised (in shares)	(435,264)	(269,167)
Warrants exercised, weighted average exercise price (in dollars per share)	$ 0.35	$ 0.10
Warrants expired/canceled (in shares)	(19,637)
Warrants expired/canceled, weighted average exercise price (in dollars per share)
Outstanding (in shares)	1,716,066	1,726,522
Outstanding, weighted average exercise price (in dollars per share)	$ 25.23	$ 29.88
Exercisable (in shares)	1,646,214	1,656,668
Exercisable, weighted average exercise price (in dollars per share)	$ 22.91	$ 27.80

Note 10 - Stockholders' Equit_4

Note 10 - Stockholders' Equity - Stock-based Compensation (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Stock-based compensation	$ 614,000	$ 652,000
Cost of Sales [Member]
Stock-based compensation	3,000	15,000
Selling and Marketing Expense [Member]
Stock-based compensation	185,000	63,000
Research and Development Expense [Member]
Stock-based compensation	98,000	136,000
General and Administrative Expense [Member]
Stock-based compensation	$ 328,000	$ 438,000

Note 10 - Stockholders' Equit_5

Note 10 - Stockholders' Equity - Option Activity for Stock Option Plans (Details) - USD ($)	Apr. 07, 2019	Dec. 14, 2018	Dec. 31, 2019
Outstanding at January 1, 2019 (in shares)			302,368
Outstanding at January 1, 2019 (in dollars per share)			$ 13.99
Granted, options (in shares)	800,000	214,000	11,450
Granted, weighted average exercise price, options (in dollars per share)	$ 0.65	$ 2.979	$ 4.38
Forfeited/cancelled (in shares)			(22,011)
Forfeited/cancelled, weighted average exercise price, options (in dollars per share)			$ 9.42
Outstanding, options (in shares)			291,807
Outstanding, weighted average exercise price, options (in dollars per share)			$ 13.96
Outstanding, weighted average remaining contractual life, options (Year)			8 years 109 days
Outstanding, aggregate intrinsic value, options			$ 280,000
Vested and Expected to Vest, options (in shares)			224,102
Vested and Expected to Vest, weighted average exercise price, options (in dollars per share)			$ 15.72
Vested and Expected to Vest, weighted average remaining contractual life, options (Year)			8 years 73 days
Vested and Expected to Vest, aggregate intrinsic value, options			$ 203,000
Exercisable, options (in shares)			147,124
Exercisable, weighted average exercise price, options (in dollars per share)			$ 19.79
Exercisable, weighted average remaining contractual life, options (Year)			7 years 328 days
Exercisable, aggregate intrinsic value, options			$ 115,000

Note 10 - Stockholders' Equit_6

Note 10 - Stockholders' Equity - Non-vested Stock Options Activity (Details) - $ / shares	Apr. 07, 2019	Dec. 14, 2018	Dec. 31, 2019	Dec. 31, 2018
Outstanding at January 1, 2019 (in shares)			302,368
Granted (in shares)	800,000	214,000	11,450
Granted (in dollars per share)			$ 3.30	$ 3.20
Vested (in shares)			(300,000)
Cancelled/forfeited (in shares)			(22,011)
Cancelled/forfeited (in dollars per share)			$ 9.42
Outstanding, options (in shares)			291,807	302,368
Non-vested Stock Options [Member]
Outstanding at January 1, 2019 (in shares)			212,172
Outstanding at January 1, 2019 (in dollars per share)			$ 6.39
Granted (in shares)			11,450
Granted (in dollars per share)			$ 3.30
Vested (in shares)			(63,675)
Vested (in dollars per share)			$ 6.73
Cancelled/forfeited (in shares)			(15,264)
Cancelled/forfeited (in dollars per share)			$ 2.74
Outstanding, options (in shares)			144,683	212,172
Outstanding at December 31, 2019 (in dollars per share)			$ 6.38	$ 6.39

Note 10 - Stockholders' Equit_7

Note 10 - Stockholders' Equity - Schedule of Assumptions (Details)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Expected life (years) (Year)	5 years	6 years
Risk-free interest rate	1.68%	2.70%
Expected volatility	103.00%	103.00%
Dividend yield	0.00%	0.00%

Note 11 - Concentrations (Detai

Note 11 - Concentrations (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Accounts Receivable, after Allowance for Credit Loss, Current, Total	$ 1,278,000	$ 1,509,000
Revenue from Contract with Customer, Including Assessed Tax	$ 12,160,000	$ 9,003,000
Supplier Concentration Risk [Member] | Cost of Goods and Service Benchmark [Member] | Supplier 1 [Member]
Concentration Risk, Percentage	57.00%	43.00%
Supplier Concentration Risk [Member] | Cost of Goods and Service Benchmark [Member] | Supplier 2 [Member]
Concentration Risk, Percentage	18.00%	14.00%
Customer 1 [Member]
Accounts Receivable, after Allowance for Credit Loss, Current, Total	$ 337,000	$ 494,000
Revenue from Contract with Customer, Including Assessed Tax	$ 3,575,000	$ 2,120,000
Customer 1 [Member] | Customer Concentration Risk [Member] | Accounts Receivable [Member]
Concentration Risk, Percentage	26.00%	33.00%
Customer 1 [Member] | Customer Concentration Risk [Member] | Revenue Benchmark [Member]
Concentration Risk, Percentage	28.00%	22.00%
Distributor 1 [Member]
Accounts Receivable, after Allowance for Credit Loss, Current, Total	$ 177,000	$ 229,000
Revenue from Contract with Customer, Including Assessed Tax	$ 1,470,000	$ 861,000
Distributor 1 [Member] | Customer Concentration Risk [Member] | Accounts Receivable [Member]
Concentration Risk, Percentage	14.00%	15.00%
Distributor 1 [Member] | Customer Concentration Risk [Member] | Revenue Benchmark [Member]
Concentration Risk, Percentage	11.00%	9.00%
Distributor 2 [Member]
Accounts Receivable, after Allowance for Credit Loss, Current, Total	$ 170,000	$ 220,000
Distributor 2 [Member] | Customer Concentration Risk [Member] | Accounts Receivable [Member]
Concentration Risk, Percentage	13.00%	15.00%

Note 11 - Concentrations - Summ

Note 11 - Concentrations - Summary of Net Equipment by Geographic Area (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Property, Plant, and Equipment Concentration	$ 2,028,000	$ 2,562,000
Geographic Concentration Risk [Member] | UNITED STATES
Property, Plant, and Equipment Concentration	1,108,000	1,614,000
Geographic Concentration Risk [Member] | COSTA RICA
Property, Plant, and Equipment Concentration	582,000	601,000
Geographic Concentration Risk [Member] | INDIA
Property, Plant, and Equipment Concentration	225,000	211,000
Geographic Concentration Risk [Member] | All Other Countries [Member]
Property, Plant, and Equipment Concentration	$ 113,000	$ 136,000

Note 12 - Segment Reporting (De

Note 12 - Segment Reporting (Details Textual)	12 Months Ended
	Dec. 31, 2019
Number of Reportable Segments	2

Note 12 - Segment Reporting - S

Note 12 - Segment Reporting - Summary of Operating Results by Reportable Segments (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Net revenues	$ 13,047,000	$ 9,672,000
Cost of revenues	7,351,000	7,479,000
Gross profit	5,696,000	2,193,000
Operating expenses	10,429,000	45,738,000
Operating loss	(4,733,000)	(43,545,000)
Depreciation and amortization	805,000	670,000
Stock-based compensation expense	614,000	652,000
Goodwill	781,000	781,000	$ 13,976,000
Total assets	15,214,000	14,611,000
Clinical Development [Member]
Net revenues	90,000	203,000
Clinical Development [Member] | Operating Segments [Member]
Net revenues	12,957,000	9,469,000
Cost of revenues	7,175,000	7,205,000
Gross profit	5,782,000	2,264,000
Operating expenses	7,081,000	8,398,000
Operating loss	(1,299,000)	(6,134,000)
Depreciation and amortization	530,000	398,000
Stock-based compensation expense	393,000	179,000
Goodwill	781,000	781,000
Total assets	13,420,000	10,815,000
Device [Member]
Net revenues	12,957,000	9,469,000
Device [Member] | Operating Segments [Member]
Net revenues	90,000	203,000
Cost of revenues	176,000	274,000
Gross profit	(86,000)	(71,000)
Operating expenses	3,348,000	37,340,000
Operating loss	(3,434,000)	(37,411,000)
Depreciation and amortization	275,000	272,000
Stock-based compensation expense	221,000	473,000
Goodwill
Total assets	$ 1,794,000	$ 3,796,000

Note 12 - Segment Reporting -_2

Note 12 - Segment Reporting - Sales to Customers (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Net revenues	$ 13,047,000	$ 9,672,000
UNITED STATES
Net revenues	6,787,000	4,854,000
Asia - Other [Member]
Net revenues	2,108,000	1,717,000
Europe [Member]
Net revenues	1,233,000	1,165,000
CHINA
Net revenues	2,346,000	1,143,000
All Other Countries [Member]
Net revenues	$ 573,000	$ 793,000

Note 13 - Income Taxes (Details

Note 13 - Income Taxes (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Income (Loss) from Continuing Operations before Income Taxes, Domestic	$ (9,934,000)	$ (45,458,000)
Income (Loss) from Continuing Operations before Income Taxes, Foreign	(150,000)	(212,000)
Income Tax Expense (Benefit), Total	0	(4,730,000)
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	(681,000)	$ (2,266,000)
Domestic Tax Authority [Member]
Operating Loss Carryforwards, Total	121,195,000
Operating Loss Carryforwards, Subject to Expiration	109,293,000
Operating Loss Carryforwards, Not Subject to Expiration	11,902,000
Domestic Tax Authority [Member] | Research Tax Credit Carryforward [Member]
Tax Credit Carryforward, Amount	1,591,000
State and Local Jurisdiction [Member]
Operating Loss Carryforwards, Total	43,870,000
State and Local Jurisdiction [Member] | Research Tax Credit Carryforward [Member]
Tax Credit Carryforward, Amount	1,476,000
Foreign Tax Authority [Member]
Operating Loss Carryforwards, Total	$ 2,495,000

Note 13 - Income Taxes - Reconc

Note 13 - Income Taxes - Reconciliation of Federal Income Tax Attributable to Operations to Income Tax Expense (Benefit) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Statutory federal income tax benefit	$ (2,118,000)	$ (9,591,000)
Intangible assets	673,000	3,119,000
Change in valuation allowance	(681,000)	(2,084,000)
Expiration of net operating losses	1,187,000	1,271,000
United States tax reform rate change
Disallowed financing costs	1,119,000	240,000
State and local taxes	(205,000)	2,344,000
Other	25,000	(29,000)
Total income tax benefit	$ 0	$ (4,730,000)

Note 13 - Income Taxes - Compon

Note 13 - Income Taxes - Components of Company's Deferred Tax Assets and Liabilities for Federal and State Income Taxes (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Deferred tax assets:
Net operating loss carryforwards	$ 26,758,000	$ 27,312,000
Income tax credit carryforwards	2,757,000	2,769,000
Stock compensation	384,000	850,000
Lease Obligation	185,000
Deferred Revenue	419,000
Other	943,000	1,027,000
Total deferred tax assets	31,446,000	31,958,000
Deferred tax liabilities
Indefinite lived intangible assets
Depreciation and amortization	(408,000)	(419,000)
Lease asset	(180,000)
Total deferred tax liabilities	(588,000)	(419,000)
Valuation allowance	(30,858,000)	(31,539,000)
Net deferred taxes

Note 14 - Employee Retirement_2

Note 14 - Employee Retirement Plan (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Defined Benefit Plan, Plan Assets, Contributions by Employer	$ 0	$ 0

Note 15 - Subsequent Events (De

Note 15 - Subsequent Events (Details Textual) - USD ($)	Feb. 13, 2020	Mar. 17, 2020	Dec. 31, 2019	Dec. 31, 2018	May 15, 2017
Convertible Notes Payable, Total			$ 413,000
Short Term Investment Minimum					$ 2,000,000
The Note [Member]
Interest Payable			1,869,000
Convertible Notes Payable, Total			$ 1,131,000
Subsequent Event [Member]
Short Term Investment Minimum		$ 1,000,000
Subsequent Event [Member] | The Note [Member]
Convertible Notes Payable, Total	$ 7,582,000
Conversion of Convertible Promissory Note into Common Stock [Member] | Subsequent Event [Member]
Debt Conversion, Original Debt, Amount	$ 3,000,000
Debt Conversion, Converted Instrument, Shares Issued	1,666,670
Debt Conversion, Converted Instrument, Price Per Share	$ 1.80